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ABSTRACT
The Use of Nucleotide Salvage Pathway Enzymes as Suitable Tumor Targets for AntibodyBased and Adoptive Cell Therapies
Edwin J. Velazquez
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
Despite the progress made in cancer research, cancer remains one of the leading causes of
death worldwide. Although the development of new cancer treatments has improved cancer
patients' survival rate, a significant number of patients experience refractory and recurrence
events with serious side effects. It is known that the immune system actively participates in
eliminating cancer. However, cancer cells can develop mechanisms to evade the immune system
resulting in immunotolerance. Immunotherapy aids the patient's immune system's ability to
recognize and eliminate cancer cells. During the last three decades, immunotherapy has
gradually emerged as an effective and more specific approach to treat cancer. Particularly
monoclonal antibodies and adoptive cell therapies such as chimeric antigen receptor (CAR) Tcells have proven highly effective. Nevertheless, the success of these novel therapies depends on
discovering suitable tumor targets. Recently, we reported localization of Thymidine Kinase 1
(TK1) to the plasma membrane of certain cancer cells but have not found such localization on
normal cells. Similarly, another nucleotide salvage pathway enzyme Hypoxanthine Guanine
Phosphoribosyltransferase (HPRT), has also been reported to be localized to the plasma
membrane of certain cancer cells. Thus, TK1 and HPRT membrane-associated forms can be
potential tumor targets for cancer immunotherapy.
This dissertation describes the immunotargeting of TK1 for the selective elimination of
tumor cells and the surface localization of HPRT on the plasma membrane of cancer cells. Using
hybridoma and phage display technologies, we developed monoclonal antibodies (mAb) and
isolated human single domain antibodies (sdAb) specific to human TK1. We confirmed that
antibodies and sdAbs could target TK1 on the plasma membrane of lung, breast and colon cancer
cells, but not on healthy cells. In addition, we demonstrated that cancer cells expressing
membrane-associated TK1 (mTK1) co-cultured with human mononuclear cells (MNC) were
selectively eliminated through antibody-dependent cell-mediated cytotoxicity (ADCC) when
anti-TK1 mAbs were added. Furthermore, we designed novel TK1 specific tumor targeting
receptors and expressed them in human T cells and human macrophages. Finally, we proposed
using both TK1 and HPRT as biomarkers for the early detection and monitoring of follicular
lymphoma (FL), a disease that is usually detected at advanced stages. The knowledge generated
from the data presented in this dissertation indicates that TK1 and HPRT may be suitable
immunotherapeutic targets for antibody-based and adoptive cell-based therapies against both
liquid and solid malignancies. It also proposes the incorporation of TK1 and HPRT as molecular
biomarkers for the early detection and monitoring of FL.
Keywords: Thymidine Kinase 1, Hypoxanthine Guanine Phosphoribosyltransferase, tumor
biomarker, monoclonal antibody, single domain antibody
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CHAPTER 1: Introduction to the clinical relevance of the nucleotide salvage pathway enzymes
and their potential as tumor targets for cancer immunotherapy.
This chapter introduces TK1 and HPRT and their role in nucleotide salvage pathways and as
potential cancer biomarkers. It also describes the initial findings of surface localization of TK1
and HPRT to the cell membrane. Finally, it discusses their potential as cancer immunotherapy
targets for antibody-based and adoptive cell therapies. We reported this evidence in three
scientific publications. The publications, where I share partial authorship with other members of
our research group have been included in this dissertation document as appendixes 1-3.
Wherever appropriate, the work of other authors has been properly cited.
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Abstract
Nucleotides are essential biomolecules that constitute the building blocks of DNA.
However, nucleotides also participate in different processes in mammalian cells, including
energetic metabolism, cell to cell communication, healing, enzymatic regulation, and immune
modulation. Nucleotides can be synthesized through the de novo pathway and the salvage
pathway. It is known that cancer cells rewire the de novo and salvage pathways to keep a
constant flow of nucleotides to meet their enhanced metabolic demands. This metabolic rewiring
in cancer cells results in nucleotide synthesis enzymes' upregulation. Thus, nucleotide synthesis
enzymes have become appealing molecular targets for the development of cancer therapies. In
recent years, two nucleotide synthesis enzymes from the salvage pathway, thymidine kinase 1
(TK1) and hypoxanthine phosphoribosyltransferase (HPRT), have increased in their clinical
relevance. Both TK1 and HPRT enzymes have shown to be upregulated in various liquid and
solid malignancies. Moreover, multiple studies have demonstrated the usefulness of TK1 and
HPRT as cancer biomarkers for the early detection of disease and monitoring of cancer patients.
Recently, we have reported the localization of TK1 and HPRT to the cell membrane of malignant
cells, but not on normal cells. This chapter discusses the clinical relevance of TK1 and HRPT as
cancer biomarkers and their potential use as therapeutic targets for antibody-based and cell
adoptive therapies.
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Introduction
The role of nucleotides in cell metabolism
Nucleotides are essential biomolecules that serve as building blocks for DNA and RNA
molecules1. However, in mammalian cells, nucleotides also participate in multiple cellular
processes, including cell signaling, energy metabolism, cell and organ healing, and cell to cell
communication2,3. In addition, nucleotides participate as structural components of coenzymes,
regulate enzymatic activity, and act as carriers of carbohydrates, amino acids, lipids, sulfate, and
methyl groups1,4. Furthermore, nucleotides are ubiquitous molecules that are present
intracellularly, and in the extracellular environment, where their concentrations significantly
influence cell homeostasis and immune cell function (Fig. 1-1)5,6.

Figure 1-1. The role of nucleotides in cell metabolism.Nucleotides are essential molecules composed of a sugar
(ribose or deoxyribose) linked to a nitrogen base and phosphate molecules. Nucleotides play an essential role in cell
metabolism, cell to cell communication, tumor microenvironment, cell and organ healing, enzymatic activity,
protein, and nucleic acid synthesis.
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Structurally, nucleotides are composed of one of the five nitrogen bases; adenine,
thymine, guanine, cytosine (only in DNA), or uracil (only in RNA) linked to a sugar molecule
(deoxyribose or ribose) and one phosphoric acid (Fig. 1-2)7. When cells need to repair their DNA
or proliferate, an increase in the demand for nucleotides occurs due to DNA replication, RNA
production, and protein synthesis. Thus, to maintain homeostasis and meet their metabolic
demands, cells replenish and keep a balanced supply of nucleotides using energy-demanding,
and strongly regulated nucleotide synthesis processes8.

Figure 1-2. The chemical structure of nucleotides. Nucleotide molecules are composed of a sugar (ribose in the case
of RNA and deoxyribose in the case of DNA), a nitrogen base (pyrimidine or purine) linked to the sugar molecule
through its 1’ carbon, and one or more phosphate groups attached to the 5’ carbon. There are three known
pyrimidines: cytosine, thymine, and uracil, and two purines: Adenine and Guanine.
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There are two metabolic pathways through which nucleotides can be synthesized, the de
novo and the salvage pathway. In the de novo pathway, each nucleotide component is
synthesized from small intracellular organic molecules such as activated ribose (PRPP), amino
acids, ATP, and carbonate9,10. However, the metabolic energy required for this pathway is high
since it utilizes energy from both glycolysis and oxidative phosphorylation8. A detailed and
elegant description of the de novo pathway can be found in a mini-review article written by
Robinson et al. 11. In the second metabolic pathway, the salvage pathway, the nitrogen bases
from existing nucleosides and nucleobases are recycled. Thus, cells can save energy by
reutilizing bases derived from catabolic reactions to make new nucleotides12. This recycling is
facilitated by enzymes such as adenine phosphoribosyltransferase (APRT), hypoxanthineguanine phosphoribosyltransferase (HPRT), thymidine phosphorylase (TP), cytidine deaminase
(CDA), uridine-cytidine kinase (UCK1), deoxycytidine kinase (DCK), and thymidine kinase 1
(TK1)13-19.

Dysregulation of nucleotide synthesis enzymes in cancer
Since cancer cells are generally fast-growing, they have a high demand for DNA, RNA,
and protein molecules as well as energy molecules such as, ATP and GTP. As a result, cancer
cells often have dysregulation of nucleotide synthesis enzymes because of their high demand for
nucleotides20. Alteration in the expression levels of nucleotide synthesis enzymes can lead to
perturbations in the nucleotide pools of cells. These perturbations can result in exogenous
addition of surplus deoxynucleosides, which causes the misincorporation of bases into DNA21.
Thus, dysregulation of nucleotide synthesis enzymes can fuel genome instability and malignant
transformation in cells. Multiple studies have shown that multiple enzymes from the de
5

novo purine and pyrimidine synthesis pathways are upregulated in cancer cells, resulting in
significantly higher quantities of nucleotides being produced to meet the demands of tumor
cells22. Among the enzymes that are upregulated in the de novo nucleotide synthesis pathway are
thymidylate synthase and inosine synthetase, which are upregulated via MYC transcription
factor23. There are other enzymes such as phosphoribosyl aminoimidazole succinocarboxamide
synthase (SAICAR synthetase), glutaminase (GS1) and phosphoribosyl pyrophosphate
amidotransferase (PPAT) that have also been shown to be upregulated in the de novo nucleotide
synthesis pathway24,25. Scientific evidence indicates that the dysregulation of the de novo
pathway is influenced by a combination of oncogenes and tumor suppressors genes, including
ras, akt, ampk, and mtor20.

The relevance of nucleotide salvage pathway enzymes in cancer
Although most of the research involving nucleotide synthesis enzymes in cancer has been
focused on enzymes from the de novo pathway, there is evidence that in many cases cancer cells
may have a higher preference to use enzymes from the salvage pathway compared to enzymes
from the de novo pathway26. Early studies conducted by Weber et al. showed that malignant cells
had higher nucleotide salvage pathway enzyme activity than enzymes from the de novo
pathways during neoplastic transformation and in hepatomas27. Another study done by Qi et al.
showed that differential expression of 5’-nucleotidase (5NUC) and the xanthine
oxidase/dehydrogenase (XD) enzymes resulted in increased usage of the salvage pathway in
colorectal carcinoma28. Dysregulation of the salvage pathway enzymes has been observed in
lymphocytic and myeloid leukemia cells when compared to normal leukocytes29. Other studies
have repeatedly shown increased levels of nucleotide salvage pathway enzymes in malignant
6

cells due to chromosome imbalance and alteration in gene regulatory elements30. These
observations suggest that targeting the salvage pathway enzymes may be used as a suitable
approach for cancer treatment. Several substrate analogs have been developed to target enzymes
involved in the salvage pathway including, 5-fluorouracil (5-FU), trifluridine (FTD), 13fluorouracil, gemcitabine, and cytarabine31,32. In addition, multiple studies have explored the
targeting of salvage pathway enzymes using RNA silencing and CRISPR tools33-36. As a result of
these investigations, nucleotide salvage pathway enzymes have increased in clinical
relevance37,38.

Two nucleotide salvage pathway enzymes, TK1 and HPRT have been shown to be
dysregulated in both hematological and solid malignancies, and their expression levels correlate
with cancer progression and patient prognosis36,39-41. Most recently, TK1 and HPRT have been
reported to be localized on the plasma membrane of multiple cancer cell lines, including tumor
cells from clinical samples42-46. These new findings suggest that TK1 and HPRT may have
potential not only as tumor biomarkers, but also as cancer immunotherapy targets. This
dissertation describes the use of the nucleotide salvage pathway enzymes TK1 and HPRT as
potential tumor targets for cancer immunotherapy. Furthermore, it proposes the use of TK1 and
HPRT as biomarkers for the early detection and monitoring of FL.

Thymidine kinase 1

TK1 is a cell cycle-regulated salvage pathway enzyme involved in the synthesis and
repair of DNA47. It specifically catalyzes the phosphorylation of deoxythymidine to
deoxythymidine monophosphate (dTMP), which is then phosphorylated by thymidylate kinase48,
7

producing deoxythymidine diphosphate (dTDP), and then nucleoside diphosphate kinase
converts dTDP to deoxythymidine triphosphate (dTTP)49. The tk1 gene is located on
chromosome 17 (17q25), and its expression and activity are tightly regulated throughout the cell
cycle, remaining low in G0 and early G1 and then significantly increasing during late G1/G2
phases with its maximum peak occurring during S phase, after which it is degraded in the mitotic
phase30,50.

TK1 regulation in healthy cells is a complex process at both genetic and protein levels.
However, in cancer cells, this regulation is disrupted, and TK1 is upregulated at all cell cycle
stages51. Several explanations have been proposed for the upregulation of tk1 gene expression
involving inversion of sequences in its promoter, point mutations in phosphorylation sites, loss
of regulatory elements in its coding sequence, or simply a chromosome imbalance30. Because
TK1 is upregulated in multiple cancers, and is present in cancer patients' serum, it has acquired
relevance as a cancer biomarker52-54. Scientific research has shown that the levels and activity of
TK1 enzyme in serum (sTK1) significantly increase in cancer patients as an early event in the
development of malignancy55-57. These levels correlate directly with cancer stage, 26,53 thus
allowing the possible monitoring of disease progression. Together, the staining of malignant
tissues and the quantification of sTK1, have demonstrated that TK1 is a reliable cancer
biomarker. Initially, several studies have shown that TK1 levels in serum could be used for the
diagnosis and prognosis of patients with hematological malignancies, including non-Hodgkin's
lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic and myeloid leukemia58-62.
However, it has also been shown that sTK1 and tk1 mRNA levels are useful for diagnosis and
monitoring of cancer patients with solid malignancies such as breast cancer, lung cancer, colon
8

cancer, malignant melanoma, gastric cancer, head and neck squamous carcinoma (HNSCC),
liver cancer, and pancreatic cancer31,63-68. In addition to its capacity to monitor cancer patients,
studies involving a significant number of patients have demonstrated that TK1 enzyme levels can
be used to detect premalignant tissues, predict response to therapy, predict survival, and
anticipate relapse events69-72. Moreover, when TK1 is combined with other biomarkers such as
Ki67, prostate specific antigen (PSA), or carcinoembryonic antigen (CEA), cancer diagnosis
precision increases73,74.

As TK1 concentration increases, the enzyme tends to make homomeric complexes of two
and four identical chains that differ in their enzymatic activity. The tetrameric form is about 100
kDa, while the dimeric form is 50 kDa75. The tetrameric form has approximately 30-fold higher
activity than the dimeric form (Fig. 1-3)50. TK1 activation states are dependent on the
concentration of ATP and thymidine. At concentrations of 2-3 mM of ATP and higher
concentrations of thymidine (15-17 μM), TK1 is present as a dimer, while at lower
concentrations of thymidine (0.5 μM), it is a tetramer. ATP presence is also required for the
tetrameric form. However, at concentrations above 0.2 mg/ml of the enzyme, TK1 tends to
oligomerize in its tetrameric form in an ATP-independent manner76. TK1 activation states are
also influenced by the cell cycle, the status of the P53 gene, and concentrations of dTTP. When
dTTP and ATP are both bound to TK1, its enzymatic activity is inhibited.77
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Figure 1-3. The crystal structure of TK1 and its active site. A) Tetrameric form of TK1 obtained from the 1XBT
crystal structure in the protein database (PDB). B) The active site of the TK1 enzyme where one thymidine molecule
binds and is phosphorylated. C) Regulation of TK1 activity through the cell cycle, modified from Munch-Petersen et
al.50

In cancer cells, TK1 has higher activity when compared to TK1 in normal cells78. It has
been reported that TK1 has isoenzymes that are specific to malignancy, whose activity appears to
be higher than TK1 from normal cells59. Some studies have reported TK1 molecular forms of 45
kDa and 200 kDa in leukemic cells 79. In addition, analysis of serum from cancer patients has
revealed TK1 complexes of higher molecular weight than its tetrameric form (100 kDa), ranging
from 200 kDa to 720 kDa78,80. This suggests that TK1 may have a tendency to homooligomerize, complex with other proteins, or present different forms in cancer cells that are not
present in healthy cells. Recently, we have reported that monomeric and dimeric forms of TK1
were able to associate with the cell membranes of Burkitt’s lymphoma and acute lymphoblastic
leukemia cells42,81. When analyzed in scanning electron microscopy (SEM), the non-Burkitt’s
10

lymphoma cell line Raji showed surface binding of anti-TK1 antibody significantly higher than
that of normal lymphocytes. Further staining of mononuclear cells (MNCs) from acute
lymphoblastic leukemia (ALL) patients with anti-TK1 mAbs revealed a positive population for
TK1 surface expression varying from 8% to 43.5% (averaging 28.01%). The study also
demonstrated that TK1 found on the cell membrane fraction of Raji, Jurkat, and HL60 cell lines
had activity (using a traditional TK1 radio assay) while negligible TK1 activity levels were
found on the membrane fraction of normal MNCs (see appendix 1)43.

After confirming that TK1 overexpression on the cell membrane of malignant cells had
clinical relevance for hematological malignancies, we decided to explore if solid tumors also
presented TK1 localization to the plasma membrane. In a further study, we found that in the
cancer cell lines NCI-H460 (lung), HT-29 (colon), and MDA-MB-231 (breast), all had localized
TK1 in the plasma membrane 82. In addition to multiple cell lines, we also analyzed cells from
both patient’s colon tumor tissue and healthy colon tissue. The isolated colon cells were analyzed
for surface expression of TK1. Flow cytometry analysis revealed that malignant colon cells from
colon cancer patients had significantly higher levels of TK1 on the cell membrane than colon
cells from healthy patients (P=0.0002, N=7) (see appendix 2). These results suggested that TK1
had clinical relevance not only in hematological malignancies but also in solid malignancies. It
also showed that the association of TK1 to the cell membrane seems to be an event restricted to
malignancy but may not be present in all malignancies. Thus, the scientific evidence suggests
that membrane-associated TK1 (mTK1) is a potential target for cancer immunotherapy and could
be used in mono or dual targeting. The development of therapeutics such as antibody fragments
or chimeric antigen receptor (CAR) specific for TK1 holds potential for the treatment of liquid
and solid cancers.
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Hypoxanthine guanine phosphoribosyltransferase (HPRT)

Purines participate in multiple cellular processes including, the production of energy, the
purinergic signaling, and as cofactors of enzymes that sustain cell growth and proliferation83,84.
In the extracellular environment and on the cell membranes, purines also participate in immune
responses and host-tumor interactions85,86. An appropriate supply of purines is necessary to
maintain various cellular activities, including proliferation and function of mitochondria, and
activation or inhibition of apoptosis87. In human cells, purines are supplied through the de novo
and salvage pathways. These two pathways maintain the cellular pools of adenylate and
guanylate via synthesis and degradation of purine nucleotides88. However, because the de novo
purine synthesis is an energy-demanding metabolic pathway, the majority of the purines are
generated by recycling of degraded bases with the help of the salvage pathway enzymes HPRT
and adenine phosphoribosyltransferase (APRT)37.

HPRT is a useful enzyme as it can synthesize precursors for adenosine triphosphate
(ATP) and guanosine triphosphate (GTP). The mechanism through which HPRT recycles
nucleotides invovles transferring a phosphoribosyl group from phosphoribosylpyrophosphate
(PRPP) to hypoxanthine and guanine bases to form inosine monophosphate (IMP) and guanine
monophosphate (GMP), respectively89. The human hprt1 gene is 47,827 bp and resides in the
long arm of the X chromosome, specifically at the Xq26.2-q26.3 locus90. The protein is 217
amino acids long and is composed of ten β strands and six α helices. The enzyme contains a core
region of a twisted parallel β sheet of five β stands surrounded by four α helices which resemble
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a nucleotide-binding pocket (amino acids 137-189). This pocket is where the GMP molecule
binds, apparently through a hydrogen bond with amino acid Lys-165 (Fig 1-4)91.

Figure 1-4. The crystal structures of HPRT in its tetrameric and monomeric forms. HPRT in its active form is a
tetramer composed of four identical chains. The monomeric form is shown on the right, with GMP bound to the
enzyme's active site. The active site of HPRT is a characteristic nucleotide-binding pocket similar to other
nucleotide synthesis enzymes.

Besides its role as a salvage pathway enzyme, HPRT has received attention due to its
participation in other relevant processes, including neuronal development, supporting of
hematopoietic stem cell function, and sustained proliferation of tumor cells92-95. Initially, HPRT
was mainly considered to be a reporter gene for mutagenesis and endogenous control for gene
expression assays96. However, recent studies conducted by several research groups including
ours, indicate that HPRT has an emerging role as a cancer biomarker and could be a potential
therapeutic target for several cancers. Previously, we observed that TK1 upregulation was an
early event in malignancy, and that TK1 levels in serum of cancer patients correlated with the
stage of disease39. Therefore, we wondered whether other salvage pathway enzymes were
upregulated along with TK1. Initial studies conducted in our lab by Townsend et al.
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demonstrated that tissue in a subset of patients with lung, colon, breast, and prostate cancers had
HPRT protein levels elevated when compared to normal tissues97. Further Western blot analyses
of HPRT protein in cancer cells indicated that lung, breast, colon, prostate cancer and nonBurkitt’s lymphoma cells showed significantly higher HPRT expression levels when compared
to those of healthy MNCs. In addition, these analyses revealed a possible relationship with the
expression levels of P53, indicating increased levels of both p53 and HPRT in breast, colon,
prostate, and non-Burkitt’s lymphoma cancer cells (Fig 1-5).

In addition to protein levels, analysis of hprt1 mRNA levels in breast, colon, lung,
prostate cancers, and normal tissues also showed significant differences between normal and
cancerous tissues. These findings have directly led to the conclusion that hprt1 is not an
appropriate housekeeping gene for cancer-related studies, but more importantly, that HPRT
protein may be useful as a cancer biomarker98. A further study was conducted at Texas Tech
University involving the analysis of hprt1 mRNA expression levels in all cancers using The
Cancer Genome Atlas (TCGA) database41. This study confirmed that when hprt1 mRNA levels
in various cancers were compared to those found in normal tissues from the GTEx database,
hprt1 mRNA levels were upregulated across all cancers compared to healthy tissues (Fig 1-6).
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Figure 1-5. Levels of HPRT enzyme and P53 protein in lung, breast, colon, prostate, and non-Burkitt’s lymphoma
cancer cells compared to normal MNCs.

Figure 1-6. Expression of hprt1 mRNA levels across all cancers from TCGA database. The mRNA levels of hprt1
are compared with the hprt1 levels in normal samples from the Genotype-Tissue Expression (GTEx) database. All
cancers from the TCGA database showed upregulation of HPRT. Modified from Sedano et al99.

Although the discovery of HPRT upregulation in malignant tissue was insightful, the
mechanism through which HPRT is upregulated in cancer and its role in tumorigenesis has not
yet been described. However, a recent study conducted by Wang et al. has shown a possible
mechanism through which upregulation of HPRT supports proliferation, survival, and epithelialmesenchymal transition (EMT) in neck and head squamous cell carcinoma (NHSCC). The study
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found that HPRT levels correlated with the poor prognosis of cancer patients. Furthermore,
experiments involving gain and loss of function demonstrated that depletion of HPRT activity in
cancer cells resulted in suppression of cell growth in vivo. In addition, Co-IP experiments
revealed that HPRT directly interacted with STAT3, maintaining its phosphorylation in a stable
state. It is known that STAT3 has a cancer-promoting effect in most tumors. Stabilization of
STAT3 phosphorylation by HPRT promoted IL-6 and EGFR signaling. The study proposes
HPRT as a potential therapeutic target95.

Considering the new evidence presented for HPRT, we decided to investigate further if
HPRT was also localized to the cell membrane of cancer cells. Analysis of A549 and NCI-H460
non-small cell lung cancer (NSCLC) cell lines by confocal microscopy and scanning electron
microscopy showed that HPRT was localized to the cell membrane (see appendix 3)100. Further
analysis of clinical samples from ALL samples revealed expression of HPRT (average
fluorescent population shift of 25%) on the cell membrane of malignant cells. When MNCs from
healthy donors were stained with anti-HPRT mAbs, no membrane associated HPRT (mHPRT)
was found on the plasma membrane101.

Using dissociated cells from colorectal cancer tissue, Townsend et al. further
demonstrated that HPRT surface localization was also present in solid malignancies. Flow
cytometry analysis revealed that a significant fraction of malignant colon cells was positive for
expression of mHPRT. Unlike cells coming from metastatic colon tissue, cells from healthy
colon tissue did not present mHPRT at significant levels102. This data suggested that the clinical
relevance of mHPRT as a therapeutic target may extend to both liquid and solid tumors.
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The evidence reported here reveals an emerging role of HPRT as a tumor biomarker and
as a potential target for therapy. Moreover, the localization of HPRT to the cell membrane of
tumor cells suggests that HPRT may be used as an immunotherapeutic target. The development
of molecules that can specifically target HPRT in cancer cells will enable the evaluation of
HPRT as a tumor target for both hematological and solid malignancies.

Cancer immunotherapy

While surgery, chemotherapy, radiotherapy, endocrine therapy, and tyrosine kinase
inhibitors have significantly impacted cancer survival rates, a substantial portion of patients
remain unresponsive to these therapies or experience recurrence events103. Overall,
approximately 40% of all cancer patients in the US will not survive ten years following
diagnosis104. Thus, alternative treatments are necessary, especially for those patients that are
unresponsive to standard cancer therapies. It is known that the immune system has the capacity
to eliminate cancer cells. Through receptors, ligands, and other secreted molecules, immune cells
can distinguish cancer cells from normal cells and selectively remove them in a process called
immunosurveillance105. However, as cancer progresses, it evades the immune system, through
immunosuppressing signaling and the creation of a hostile tumor microenvironment that converts
immune cells into pro-tumor activation states. This process is called immunoescape106. Cancer
immunotherapy is a paradigm-shifting approach that restores and boosts the patient’s immune
system capacity to eliminate tumor cells107. Cancer immunotherapy treatments include mAbs,
cytokines, genetically engineered T-cells and cell therapies, cancer vaccines, bi-specific T-cell
engagers, and oncolytic viruses108. During the last two decades, cancer immunotherapy has
demonstrated unprecedented success in the clinical setting and gradually reemerged as a
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powerful approach for the treatment of cancers109. As of December 2021, there were more than
4,720 drugs in development in the global immuno-oncology (IO) pipeline and approximately
11,643 active clinical trials testing cancer immunotherapy agents110. Among the leading six
classes of cancer immunotherapeutics, antibody-based and cell adoptive therapies are the two
fastest-growing groups in the IO field.

Antibody-based therapies

The development of hybridoma technology in 1975 by Georges Kohler and Cesar
Milstein at the MRC laboratories at Cambridge University was a scientific breakthrough that
marked a new era in the production of mAbs and antibody research111. Since then, monoclonal
antibodies (mAbs) have been utilized for research, diagnostic and therapeutic purposes.
Humanized mAbs have been used for the treatment of several diseases, including cancer112.
Today there are more than 2,000 mAbs being tested in the clinical setting110. As of May 2021,
the FDA has approved a total of 100 therapeutic mAbs, of which more than 30% are for the
treatment of cancer113. Antibody-based therapies can be used to target proteins that are uniquely
found on cancer cells or to block immune checkpoint molecules that tune the immune response
in the tumor microenvironment114,115. Thus, mAbs can be used to engage immune cells with
tumor cells, boosting the immune response against cancer cells by identifying markers that the
immune system can recognize, thereby stimulating an antitumor response116.
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Chimeric Antigen Receptors (CAR) T-cell therapies

CAR T-cells are genetically engineered T-cells that express a tumor-targeting receptor117.
CAR T-cells are composed of antibody fragments specific for a tumor target, a hinge connected
to a transmembrane domain, an activation domain that triggers immune cell activation, and a costimulatory domain that supports the activation of the immune cell118. In CAR T-cell therapy, Tcells are taken from the patient; they are genetically engineered to express a specific receptor
(CAR) molecule, and re-introduced into the patient119. As of November 2021, there are more
than 900 active clinical trials testing CAR T-cells and five CAR T-cell therapies approved by the
FDA120. CAR T-cell therapy has proven very successful in hematological malignancies, mainly
targeting CD19 (ORR up to ~90%), and most recently CD20 and B-cell maturation antigen
(BCMA)121,122. The success of CAR-T cell therapy in hematological malignancies has made
scientists try to extrapolate its benefits to the context of solid malignancies. Although CAR Tcell therapy has made significant progress in liquid tumors, there are several challenges related to
the nature of solid malignancies that still need to be overcome123. Among these challenges are
antigen escape and tumor heterogeneity124,125. Frequently, tumor cells have been shown to lose
expression of a particular tumor target, which renders CAR-T cells ineffective. Moreover, solid
tumors are in their majority composed of heterogeneous cell populations expressing different
markers. Hence, to be effective, future CAR T-cell therapies need to target more than one tumor
specific antigen126. Therefore, the expansion of suitable targets that can be used in both
hematological and solid malignancies continues to be critical for the success of CAR T-cell
therapy127.
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Immunotherapy needs of suitable tumor targets

Although promising, the efficacy of antibody-based and cell-based therapies is often
hampered by tumor antigen escape or off-target effects in part due to the limited number of
clinically proven targets. Thus, the discovery of novel tumor targets whose expression is
restricted to malignancy is critical to overcome some of the challenges of tumor heterogeneity,
antigen escape/loss, and to expand the spectrum of targetable tumors128. Thus, the critical initial
steps in developing effective cancer immunotherapies are: 1) The identification of specific tumor
antigens and 2) The generation of high affinity antibodies against these antigens. During the last
decade, an explosion of new targetable tumor antigens have become available on various human
malignancies127. However, a common limitation is that the majority of these tumor targets are
also expressed on normal tissues, thus precluding the successful extrapolation of antibody-based
and CAR T-cell therapies to a broader spectrum of tumor types and sometimes generating side
effects related to cytotoxicity129.

TK1 and HPRT as potential tumor targets
We have previously described the surface expression of mTK1 and mHPRT in both
hematological and solid malignancies. In tissue staining, Western blot, and mRNA studies, TK1
and HPRT have been shown to be upregulated in malignant tissue but not in normal tissue.
Moreover, surface expression of mTK1 and mHPRT seems to be present only on tumor cells and
absent or at negligible levels on healthy cells. Therefore, TK1 and HPRT may be suitable
immunotherapeutic targets for antibody-based and cell-based therapies. Our hypothesis is that:
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The targeting of cancer cells with TK1- and HPRT-specific immunotherapeutics will
trigger a significant anti-tumor response by immune cells and initiate the elimination of TK1 and
HPRT positive cancer cells without attacking non-cancerous tissues (Fig.1-7).

In this dissertation we will discuss the development and preclinical evaluation of both
antibody-based and cell adoptive therapies targeting membrane associated TK1 and HPRT forms
in lung, breast, and colon cancer cells.

Figure 1-7. The use of TK1 and HPRT as suitable targets for antibody-based and cell-based cancer
immunotherapies. In this image, TK1 or HPRT is targeted with human recombinant antibodies. TK1 or HPRTspecific CAR receptors can be designed and expressed in human T cells or macrophages.

Summary of research chapters

Chapter 2 describes the immunotargeting of TK1 on the plasma membrane of cancer cells
and the development of a panel of novel mAbs against human TK1. We present preclinical data
regarding the validation of the TK1 mAbs for both diagnostic and therapeutic purposes. The
antibodies produced had high specificity and sensitivity comparable to commercially available
anti-TK1 antibodies. In addition, we found novel targetable epitopes in the TK1 molecule
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exposed on the plasma membrane of cancer cells, thus, adding new knowledge regarding the
characterization of mTK1 on cancer cells. Moreover, we provide evidence that cancer cells
expressing mTK1 can be targeted using mAbs and selectively eliminated by human MNCs
through an antibody-dependent cell-mediated cytotoxicity (ADCC) response. To our knowledge,
this is the first time that the immunotargeting of TK1 on the plasma membrane of cancer cells
has been proven as a feasible approach for the treatment of solid tumors in a preclinical context.
This paper was published in Cancer Cell International (DOI: 10.1186/s12935-020-01198-8).

In Chapter 3, we implemented phage display technology to isolate human single domain
antibodies (sdAbs), also known as nanobodies, against TK1. Although the development of mAbs
through conventional hybridoma technology has been used successfully for decades, mAbs need
further humanization before use in the clinical setting. Using human antibody libraries and phage
display technology, we describe the isolation of human anti-TK1 sdAbs from a dAb library. The
sdAbs were successfully expressed and validated through enzyme-linked immunoassays
(ELISA), Western blot, siRNA knockdown, and flow cytometry. To date, partially humanized or
completely human TK1 mAbs and dAbs have not been developed or used for the
immunotargeting of cancer cells. We demonstrate that human anti-TK1 dAbs are able to bind to
mTK1 on cancer cells. Since the anti-TK1 dAbs were ten times smaller (12kDa) than previously
developed anti-TK1 mAbs, they represent an appealing approach for targeting tumor cells. We
demonstrated that the anti-TK1 sdAbs could easily be reformatted and fused to custom
engineered human IgG Fc regions. Furthermore, we provided evidence that human engineered
anti-TK1-dAb-IgG1 antibodies can efficiently target mTK1 without the immunogenicity risks
associated with previously developed anti-TK1 mAbs from animal hosts. The data presented
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here strengthens the concept of using mTK1 as an immunotherapeutic target and proposes the
use of human anti-TK1 nanobodies versus conventional full-length antibodies. The associated
article was published in PLOS ONE (https://doi.org/ 10.1371/journal.pone.0264822).

Chapter 4 is a comprehensive but concise review of follicular lymphoma (FL) biomarkers
describing the etiology and pathology of follicular lymphoma through its different stages. We
also analyze the efforts made to develop prognostic indexes for the management of FL patients
and the existing challenges regarding early detection and management of the disease. We discuss
the current progress of follicular lymphoma biomarkers during the age of precision medicine for
early detection and prediction to therapy response. In this paper, we point out that the
development of novel cancer immunotherapy treatments requires new biomarkers and studies
that reflect FL's current course. New biomarkers for FL include circulating tumor DNA,
microRNAs, exosomes, cytokines, specific subsets of immune cells, and specific epigeneticrelated genes. We discuss the clinical relevance of the nucleotide salvage pathway enzymes as
biomarkers for hematological malignancies. We propose the use of TK1 and HPRT to be
considered potential biomarkers for the early detection of FL and the monitoring of disease, thus
expanding the cancer types where TK1 and HPRT can be utilized for diagnostic purposes.
Following peer review by a journal, the reviewers concerns are currently being addressed for
resubmission.

Summary of appendices

Appendix 1 is a scientific study published in OncoTargets and Therapy. The study
reports the surface localization of TK1 to the cell membrane of Burkkit’s lymphoma and ALL
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cells. The study further reports that surface localization of TK1 seems to be an event restricted to
malignancy. The study expands the role of TK1 from a biomarker to a potential
immunotherapeutic target for blood malignancies. (https://doi.org/10.2147/OTT.S141239)

Appendix 2 is a scientific paper published in Cancer Cell International. The study
provides evidence of TK1 expression on the cell membrane of lung, breast, and colorectal
malignancies. It reports TK1 membrane expression on HT-29, SW620, MBA-MD-231, MCF7,
NCI-H460, and A549 cells. It also demonstrates the expression of TK1 on the cell membrane of
malignant colon cells from cancer patients. TK1 expression was not found on cells from healthy
patients. The study suggests that TK1 may have potential therapeutic use as a target for solid
malignancies. (https://doi.org/10.1186/s12935-018-0633-9).

Appendix 3. Is a study published in OncoTargets and Therapy. The study describes the
initial experiments conducted to characterize the surface expression of HPRT on the cell
membrane of non-small cell lung carcinoma cells. Significant localization of HPRT was found
on both cell lines. No HPRT expression was found on cells from healthy donors. This study
suggests HPRT may have a dual role as a cancer biomarker and a therapeutic target.
(https://doi.org/10.2147/OTT.S128416).

Appendix 4 Contains data from an abstract published in Cancer Research entitled
“Development of a TK1 specific chimeric antigen receptor T-cell for the treatment of non-smallcell lung cancer”. This poster was presented at the annual meeting of the American Association
for Cancer Research in 2017, Washington DC. DOI: 10.1158/1538-7445.AM2017-5619.
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Appendix 5 contains data of an abstract published in Cancer Research entitled
“Macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive
cell therapy for the treatment of solid malignancies.” This poster was presented at the annual
meeting of the American Association for Cancer Research in 2018, Chicago.
DOI: 10.1158/1538-7445.AM2018-2563

Appendix 6 summarizes the number of publications, book chapters, and presentations at
both regional and international conferences utilizing data produced by my research. It also
contains a list of the awards received and the total amount of funding attracted through grant and
fellowship applications during the course of my Ph.D. program.
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CHAPTER 2: Novel monoclonal antibodies against thymidine kinase 1 and their potential use
for the immunotargeting of lung, breast and colon cancer cells
Citation: Velazquez EJ, Brindley TD, Shrestha G et al. Novel monoclonal antibodies against
thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon
cancer cells. Cancer Cell Int. 2020;20:127. https://doi.org/10.1186/s12935-020-01198-8.
The following chapter is taken from an article published in Cancer Cell International and
included as a book chapter at the Prime Archives in Cancer Research. All content and figures
have been formatted for this dissertation. I hereby confirm that the use of this article is
compliant with all publishing agreements.

26

Abstract
Thymidine kinase 1 (TK1) is a pyrimidine salvage pathway enzyme that is up-regulated
in malignant tissues and elevated in the serum of cancer patients. While TK1 has been well
established as a tumor biomarker, little has been done to explore its potential as a tumor target.
Recently, we reported the membrane expression of TK1 on malignant cells, but not on normal
cells. This study explores the possible use of monoclonal antibodies for the targeting of
membrane associated TK1 in lung, breast, colon and prostate cancer cells. We generated and
evaluated a panel of monoclonal antibodies against six different epitopes exposed in the
tetrameric form of TK1. Antibodies were developed with hybridoma technology and validated
with Western blot, siRNA TK1 knockdown, enzyme-linked immunosorbent assay (ELISA) and
flow cytometry. The therapeutic potential of the antibodies was evaluated in vitro in antibodydependent cell-mediated-cytotoxicity (ADCC) experiments. Binding of the antibodies to TK1
was confirmed by Western blot in purified recombinant protein, cancer serum, and cell lysate.
After a TK1 knockdown was performed, a reduction of TK1 expression was observed with five
antibodies. Using indirect ELISA, we identified 3B2E11, 9C10, 7H2, 3B4, 8G2 among the most
sensitive antibodies (LOD = 10.73–66.9 pg/ml). Surface expression of TK1 on the membrane of
various cancer cell lines was analyzed with flow cytometry. Antibodies 8G2, 3B4, 7HD and
5F7G11 detected TK1 on the membrane of various cancer cell lines, including lung, prostate,
colon and breast. No significant binding was detected on normal lymphocytes. Increased
cytolysis of lung (~ 70%. p = 0.0001), breast (~ 70%, p = 0.0461) and colon (~ 50% p = 0.0216)
cancer cells by effector cells was observed when anti-TK1 antibodies were added during ADCC
experiments. The antibodies developed showed potential to be used to detect and target TK1 on
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the membrane of various tumor cells. The targeting of TK1 in malignant cells using monoclonal
antibodies may be a feasible approach for the elimination of high TK1 expressing tumor cells.

Introduction

With the number of clinical and preclinical agents exponentially increasing every year,
cancer immunotherapy is currently one of the fastest growing areas in global oncology130. From
cell adoptive therapies to monoclonal antibodies, the efficacy of most cancer immunotherapies
primarily relies on the discovery of suitable tumor targets and the development of highly specific
agents against these targets131. During the last decade the list of tumor antigens available for
immunotherapy have gone from dozens to hundreds, allowing us to treat a broader spectrum of
human malignancies132. However, a common limitation that many of these tumor targets face is
their expression on normal tissues133. Thymidine Kinase 1 (TK1) is a cell cycle regulated DNA
synthesis enzyme that is up-regulated in malignant tissues during early stages of cancer
development134,135. Multiple studies have shown that TK1 levels in serum (sTK1) and tissues
correlate with cancer progression, patient outcome and recurrence events 136-141. Although TK1
was initially proposed as a cancer biomarker for several blood cancers 142,143, it has also been
shown to be a reliable biomarker for a wide variety of solid malignancies144-149.

While TK1 levels have been primarily used to monitor the development of malignancy, it
has been suggested that overexpression of TK1 or malignant associated forms of the enzyme
could be used for the targeting of cancer150,151. Recently, the expression of membrane associated
TK1 forms in both cancer cell lines and clinical samples has been reported. In one study it was
shown that monomeric and dimeric forms of TK1 can be detected on the cell membrane of
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mononuclear cells (MNC) from patients with acute lymphoblastic leukemia (ALL) and acute
myeloid leukemia (AML)81. While this membrane associated TK1 form was present on
malignant cells, it was absent on normal proliferating B cells81. According to another study,
membrane expression of TK1 was also found in lung cancer cell lines and cells from breast and
colon tumors82. These findings indicate that TK1 may be a potential immunotherapeutic target
for antibody-based and adoptive cell therapies.

Despite the large number of studies demonstrating the value of TK1 as a cancer
biomarker and its potential as a tumor target, there are a limited number of clinically tested
antibodies for the detection and targeting of TK1152. To our knowledge, no TK1 antibody-based
therapeutics have yet been developed or tested in a preclinical setting yet153. Moreover, most of
the existing antibodies for detection of TK1 primarily target a cell cycle regulatory region of the
TK1 molecule at the C-terminus154. It has been reported that TK1 in malignant cells has different
isoenzymes and that its activity levels differ significantly from TK1 in normal cells59,155. It is
also known that TK1 can form different complexes, with some in serum having abnormal
molecular weights of up to 240 kDa and 730 kDa156-159. Therefore, antibodies targeting only one
region of the TK1 protein may limit the detection of TK1 to specific forms of the enzyme. Thus,
the existing antibodies for TK1, may not be sufficient to detect some of the complex TK1 forms
that exist in cancer patients. Broadening the spectrum of targetable TK1 specific epitopes could
help us increase our ability to target TK1 in cancer patients.

In this study, we identified six epitopes that were exposed in the tetrameric form of TK1
and generated monoclonal antibodies specific for these regions. Seventeen antibodies were
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chosen for characterization and validation through Western blot, siRNA TK1 knockdown,
ELISA and flow cytometry. In addition, the potential of the anti TK1 antibodies for the targeting
of malignant cells was tested by measuring the antibody-dependent cell-mediated cytotoxicity
(ADCC) responses of mono nuclear cells (MNC) against high-level TK1-expressing cancer cells.

Materials and methods
Cell lines and isolation of MNC
The NCI-H460 (ATCCHTB-177™), A549 (ATCC® CCL-185), MDA-MB-231
(ATCC® CRM-HTB-26), PC3 (ATCC® CRL-7934™) and HT-29 (ATCC® HTB-38™) cell
lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA)
and maintained according to ATCC recommendations. A549, NCI-H460, PC3 and HT-29 were
cultured in RPMI-1640 media (ThermoFisher scientific, Waltham, MA) supplemented with 10%
fetal bovine serum (FBS) and 2 mM L-Glutamine. MDA-MB-231 cells were cultured in DMEM
with 2 mM L-glutamine and 10% FBS. Cell lines were grown in an incubator at 37 °C and 5%
CO2. All cell lines used were tested for TK1 surface expression with flow cytometry with a
commercial antibody Abcam (91651) (Abcam, Cambridge, UK) to confirm the presence of TK1
on the cell membrane. Human MNC were isolated from whole blood from healthy donors with
the high affinity CD16 V158 FcγIIIa receptor variant160. The CD16 V158 FcγIIIa variant was
confirmed by polymerase chain reaction (PCR) from cDNA of the donor’s MNC and DNA
sequencing. MNC were isolated with lymphocyte separation media (Corning, NY) following
manufacturer instructions, red blood cells were depleted with red blood cell lysis buffer
(Biolegend, San Diego, CA) and the MNC were resuspended in RPMI media with 2 mM Lglutamine and 10% heat inactivated human AB serum (Millipore SIGMA, St Louis, MO, USA).
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Blood withdrawal was done under the Brigham Young University’s institutional review board
approval No. 1734.

Production of recombinant TK1 in E. coli and Saccharomyces cerevisiae
The production of human TK1 was carried out in an E. coli expression system by
Genscript’s recombinant protein service. In-house production of human TK1 was done using the
pESC-URA (Genscript, Piscataway, NJ) yeast expression system and a Saccharomyces
cerevisiae yeast strain with a REG-1 mutation. Briefly, the coding sequence of the human TK1
(Genbank NM_003258.5) was synthesized and placed into the pESC-URA vector flanked by the
Sal I restriction sites. A tag of 6 histidines was included at the C-terminus of the TK1 sequence
to facilitate His-tag purification. The TK1-pESC-URA vector was introduced in
electrocompetent yeast using the lithium acetate procedure and an Eporator system (Eppendorf,
Hamburg, Germany)161. After electroporating, the cells were plated in synthetic complete (SC)
drop-out Ura-plates (Takara Bio USA Inc, Mountain View, CA) and grown for 36 h at 30 °C.
Yeast culture was scaled up to 500 ml and induced for protein expression with galactose. After
36 hr, yeast cells were harvested and lysed in lysis buffer with the Halt™ protease inhibitor
cocktail (ThermoFisher Scientific, Waltham, MA) in a French press. Recombinant TK1 was
purified from cleared lysate using NI-NTA-agarose bead columns (Qiagen, Hilden, Germany)
and validated with commercially outsourced TK1 produced in E. coli by Genscript and the
commercial anti TK1 antibody ab91651 in Western blot.
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Epitope selection
Epitopes on the active form of TK1 that could be accessible to were determined
analyzing the 1XBT crystal structure of the tetrameric form of TK1 using the PyMOL
software162 19. The epitope sequences were then analyzed using the protein BLAST tool from
NCBI with the non-redundant protein sequences and the Homo sapiens (taxid9606) data bases to
see the epitopes’ similarity with other human proteins. The sequences of the mouse, rabbit, dog
and human TK1 isoform 1 (Genebank, NM_003258.5) were aligned and analyzed using the
Geneious software to identify regions across the human TK1 sequence that significantly differ
between species163.

Production of hybridomas and selection of antibody clones
Antibodies were generated in mice and rats that were immunized with 6 different TK1
peptide sequences that were selected as described in the previous section. The peptide sequences
for TK1 and the hybridoma cell lines were produced using the monoclonal antibody generation
service MonoExpress™ Premium (Genscript, Piscataway, NJ). Briefly, the production of
hybridomas consisted of four phases as follows. Phase one was the preparation of the
immunogen. In this case the synthesis of six TK1 peptides using the PepPower™ peptide
synthesis service (Genscript, Piscataway, NJ). Phase two involved the immunization of 3–5
Balb/c mice or rats with the MonoExpress™ immunization protocol. After the immunization
regimen was completed, splenocytes were isolated and fused to myeloma cells using
polyethylene glycol (PEG) and electrofusion. The cells were then cultured in hypoxanthineaminopterin-thymidine medium (HAT) to select only the myeloma-lymphocyte hybrids. During
phase three, individual hybridoma cells were isolated through limiting dilutions and their
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supernatants were tested for binding to 1 μg/ml of each TK1 peptide used for immunization by
indirect enzyme-linked immunosorbent assay (ELISA). The ten hybridomas with the best
screening results were then selected for isotyping. The supernatants were then evaluated for
binding to TK1 in Western blotting. After antibody binding to TK1 was confirmed through
indirect ELISA and Western blotting, phase four involved the subcloning of each hybridoma by
the limiting dilution technique. Each hybridoma was then expanded and frozen. From 44
hybridomas, a total of 17 clones were selected based on Western blot and Indirect ELISA results.
The monoclonal antibodies were then purified from hybridoma supernatant with protein G and
protein L columns (ThermoFisher scientific, Waltham, MA) and eluted in phosphate-buffered
saline (PBS) buffer.

Western blot
Western blot was performed to validate the binding of the custom antibodies to TK1
using recombinant human TK1 produced with a yeast expression system to mimic the TK1
folding in human cells. The antibodies were also tested for their capacity to bind to TK1 in serum
samples from lung cancer patients. Briefly, 0.5 μg of TK1 or 15 μg of serum samples were
mixed with 6× Laemmli buffer (Millipore SIGMA, St Louis, MO). The protein samples were
then heated at 100 °C for 5 min and loaded into a 12% SDS-PAGE gel. The proteins from the gel
were then transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). After
blocking with 5% milk in PBS tween-20 (PBS-T) buffer for 1 hr at room temperature, the
blocking solution was poured out and primary antibody solution (1–2 μg/ml) was added.
Membranes were incubated at 4 °C overnight. After overnight incubation, membranes were
washed 3 times with PBS-T buffer. The bound proteins were detected using a 1:20,000 solution
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of horseradish peroxidase-conjugated (HRP) anti-mouse or anti-rat antibody (Advansta
Corporation, San Jose, CA). The proteins were then detected through the peroxidase reaction
using enhanced chemiluminescence (ECL) (Advansta Corporation, San Jose, CA). Films were
exposed for different amounts of time depending on the antibody being tested, with times
ranging from 30 s to 5 min. The films were scanned, and the images were analyzed using the
software ImageJ from NIH164.

siRNA TK1 knockdown
For our TK1 siRNA experiments we used the validated TK1 siRNA s14160
Silencer® Select (ThermoFisher Scientific, Waltham, MA). The Silencer™ GAPDH (Cat. No.
4390849) siRNA was used as positive control and the Silencer™ siRNA control No. 1 (Cat.
No.4390843) was used as negative control. A total of 2.5 × 105 MDA-MB-231 cells were seeded
in a 6 well plate and incubated overnight at 37 º C and 5% CO2. Cells were then transfected
using 7.5 μl of lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) and 30 pmol of each
corresponding siRNA following the manufacturer's protocol. After 24 hr., transfection was
repeated. Cells were harvested after 24 hr. after second transfection for subsequent experiments
and cell lysate preparations. Cell lysates were prepared using NP-40 cell lysis buffer with Halt™
protease inhibitor cocktail (100×) (ThermoFisher Scientific, Waltham, MA) and 1 mM of
phenylmethylsulfonyl fluoride (Millipore SIGMA, Burlington, MA). Lysates were cleared by
centrifugation and flash frozen with liquid nitrogen and stored at − 80 °C. The cell lysates were
then analyzed with Western blot comparing cell lysates treated with TK1 siRNA with the
GAPDH siRNA and siRNA negative controls for six custom TK1 antibodies and the commercial
TK1 antibody Ab76495 (Abcam, Cambridge, UK).
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ELISA
The sensitivity of each antibody to detect TK1 protein was estimated by indirect ELISA.
In order to determine the limit of detection (LOD), antibodies were tested with individual dose–
response curves and a four-point parameter logistic curve (4PL). Costar 96-well plates (Corning,
NY, USA) were coated overnight with 100 μl of 1:1 serial dilutions of TK1 in PBS buffer at
4 °C. Dilutions ranged from 5000 to 26 ng/ml or from 6000 to 5 pg/ml, depending on the
antibodies’ sensitivity. After overnight incubation, the plates were washed 3 times with PBS-T
and blocked for 1 h with PBS 1% BSA at room temperature on a shaker with gentle agitation.
The plates were then washed 3 times with PBS-T, and 100 μl of a 1 μg/ml solution of primary
antibody were added into each well. The plates were incubated for 1 hr. at room temp on a
shaker with gentle agitation. After incubating, the plates were washed 3 times with PBS-T, and
100 μl of a 1:40,000 dilution of secondary HRP-conjugated antibody (Advansta Corporation, San
Jose, CA) solution were added into each well. Plates were incubated for 1 h at room temperature
on a shaker. The plates were washed 3 times with PBS-T, and 100 μl of 1-step ultra TMB
substrate (ThermoFisher scientific, Waltham, MA) were added to each well. The plates were
then incubated for 10 min at room temperature, protected from light. The reaction was stopped
by adding 100 μl of 0.5 M sulfuric acid solution. The absorbance was measured using a Synergy
HT Microplate Reader (Bio-Tek Winooski, VT) at 450 nm and 650 nm. Samples were run in
triplicate and confirmed with at least two independent experiments.

From the antibodies that showed high sensitivity in indirect ELISA, multiple antibody
pairs were tested in sandwich ELISA format. One hundred μl of a 0.5 μg/ml solution of the
capture antibodies were allowed to adsorb overnight at 4 °C. After overnight incubation, the
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plates were washed 3 times with PBS-T buffer and blocked with PBS 1% BSA as previously
described. TK1 protein or cancer serum was serially diluted in PBS buffer and then allowed to
bind to the primary antibody for 1 hr at room temperature on a shaker. The wells were then
washed 3 times with PBS-T buffer and 100 μl of biotinylated detection antibody solution
(0.5 μg/ml) was added and allowed to bind for 1 hr at room temperature. After incubation, the
plates were washed with PBS-T buffer and 100 μl of Pierce high sensitivity streptavidin-HRP
solution (ThermoFisher scientific, Waltham, MA) was added to each well. The plates were
incubated for 30 min. and washed with PBS-T buffer 3 times. After washing, 100 μl of 1-step
ultra-TMB substrate solution (ThermoFisher scientific, Waltham, MA) was added to the wells
and the plates were incubated with the substrate for 10 min. The reaction was quenched by
adding 100 μl of 1 M sulfuric acid. Absorbance was measured using a Synergy HT Microplate
Reader (Bio-Tek Winooski, VT) at 450 nm and 570 nm.

For each antibody, the limit of quantification (LOQ) and the LOD were determined by
ELISA using the following formulas: LOQ = 10 (s/fʹ) and LOD = 3.3(s/fʹ) 165,166 where s is the
standard deviation from the residuals and f’ is the slope of a calibration curve. A 30% maximum
value for relative standard deviation for the concentration estimates was set for the LOD and a
10% relative standard deviation for the LOQ, according to Hayashi et al.

Flow cytometry
Surface expression of TK1 was analyzed through flow cytometry. The antibodies’
binding capacity to detect membrane associated forms of TK1 was compared to the binding
capacity of the commercial TK1 antibodies Ab91651 and Ab76495 (Abcam, Cambridge, UK).
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For the experiment, four different cancer cell lines expressing different levels of TK1 were used.
The cell lines used were the non-small cell lung carcinoma cell line NCI-H460, the breast cancer
cell line MDA-MB-231, the prostate cancer cell line PC3 and the colorectal cancer cell line HT29. Since membrane expression of TK1 appears to be restricted to malignancy, MNC from
healthy donors were used as a negative control. Each one of the cancer cell lines was stained
with each one of the anti-TK1 antibodies in at least 3 independent flow cytometry experiments.

For the analysis, cancer cells and normal MNC were collected as follows. Cancer cells
were grown as monolayer cultures using DMEM or RPMI1640 with 10% FBS and 10 mM Lglutamine. The cells were grown until they reached 70–80% confluency and detached using
accutase (ThermoFisher scientific, Waltham, MA). The cells were then collected and washed 3
times with cell staining buffer (PBS buffer, pH7.4, BSA 1% and sodium azide 0.1%). MNCs
were isolated from whole blood as previously described and washed 3 times with cell staining
buffer. All cells were resuspended at a concentration of 5 × 105 cells/ml, placed in individual
microcentrifuge tubes and incubated with 5 μl of Human TruStain Fc block (BioLegend, San
Diego, CA) for 10 min at room temperature. In the case of MNC, the cells were incubated with
10% heat inactivated human serum 30 min on ice. Unstained, isotype, and positive controls
(CD44, CD45, GAPDH) were included in all experiments. After incubation with Fc block, the
cells were stained with 1 or 2 μg of the custom and commercial TK1 antibodies and incubated
for 30 min on ice. The cells were then washed 3 times and resuspended in 100 μl of cell staining
buffer. Secondary antibodies conjugated to Alexa Fluor 647 (Abcam, Cambridge, UK) were
added and the cells were incubated on ice for another 30 min, protected from light. After
incubating with the secondary antibodies, the cells were washed 3 times, resuspended in 100 μl
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of cell staining buffer and analyzed. Dead cell discrimination was performed by adding 15 μl of a
10 μg/ml PI solution (Millipore SIGMA, St Louis, MO) 1 min before analysis. A Cytoflex flow
cytometer machine (Beckman Coulter, Brea, CA) was used to collect the data. The data analysis
was performed using FlowJo software (FlowJo, Inc., Ashland, OR).

Detection of membrane associated TK1 and isolation of plasma membrane protein
To further confirm the levels of membrane associated TK1 from cancer and normal cells,
we isolated plasma membrane protein fractions from cancer and normal cells. For this
experiment, the non-small cell lung cancer cell line NCI-H460 was chosen for presenting high
levels of membrane associated TK1. MNCs from a healthy individual were used as normal cells.
To isolate the plasma membrane protein, we used the extraction kit (Abcam, Cambridge, UK)
and followed the manufacturer’s instructions. Briefly 2 × 108 cells were harvested and gently
lysed with a Dounce homogenizer in 2 ml of lysis buffer with protease inhibitors. After lysis, the
cells were centrifuged at 700g for 10 min at 4 °C and the supernatants were transferred to a new
tube. The cleared supernatants were then centrifuged at 10,000g for 30 min at 4 °C. The
supernatant containing the cytosolic fraction was completely aspirated and the cell pellet
containing the membrane protein fraction was resuspended and mixed with upper and lower
phase solutions as instructed from the manufacturer. The total plasma membrane protein was
then quantified using the BCA assay kit (ThermoFisher scientific, Waltham, MA). A Total of 30
μg of protein for each sample was loaded into an SDS-PAGE gel. Separated proteins were
transferred to a nitrocellulose membrane and Western blots were performed as previously
described. To detect TK1, we used a validated TK1 antibody. As negative control, we used an
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anti-GAPDH antibody (Cell Signaling, Danvers, MA) and as positive control we used an antisodium/potassium ATPase antibody MA3-928 (ThermoFisher scientific, Waltham, MA).

Antibody-dependent cell-mediated cytotoxicity experiments
The capacity of the custom antibodies to elicit ADCC responses was tested in vitro. For
these experiments the A549 cell line which expresses high levels of TK1 on the cell membrane
was chosen as a target cell. To measure cell death overtime, we used the real time cell analysis
platform ExCELLigence (ACEA biosciences, San Diego, CA). The ExCELLigence platform
works on the principle of impedance. Tissue culture plates with nanogold electrodes were used to
measure impedance caused by target cells adhering to the plates. The impedance reflects cell
growth and cell viability. The cell growth is then expressed as a normalized cell index (NCI) that
is measured over time. The higher the cell index (CI), the more cell growth. A decrease in the
cell index reflects cell death or cytotoxicity caused by a treatment, in this case, an ADCC
response167. For the ADCC experiments, a max of 8 × 103 target cells were seeded in each well
in a total volume of 100 μl of RPMI media. Experiments were run for 48–72 hr. CI were
normalized to 1 at the time when effector cells and antibodies were added. After sufficient
growth (CI 0.5–1.0), 50 μl of freshly isolated MNC cells were added at different effector-target
ratios (E:T). E:T ratios of 5:1, 2.5:1, 1.25:1 and 0.625:1 were tested. After finding the optimum
E:T ratio, dose response curves were generated by testing different concentrations of the TK1
antibodies to find the minimum amount of antibody that could produce a significant increase in
specific cell death. All experiments included cells treated with the IgG2b negative control
antibody (BIO-RAD, Hercules, CA). Experiments also included controls of target cells without
antibody and a full cell lysis control. The effect of the TK1 antibodies in target and effector cells
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alone were also tested and included as additional controls. The percentage of specific cytolysis
was determined using the immunotherapy module from the RTCA pro software (ACEA
biosciences, San Diego, CA). The signal from effector and target cells with no antibody and from
effector alone was subtracted. According to the user’s manual, the software subtracts the values
from the reference wells using the following formula:

% Cytolysisst=[1−Norm(CIst−AvgEff_Sub_t)/(AvgNorm(CIRt−AvgEffR_Sub_t)]×100
% Cytolysisst=[1−Norm(CIst−AvgEff_Sub_t)/(AvgNorm(CIRt−AvgEffR_Sub_t)]×100

where Norm (CIst-AvgEff_Sub_t) is the Normalized value of the sample Cell Index
minus the Average Cell Index for the matching selected Effector alone control at time t and
AvgNorm(CIRt- AvgEffR_Sub_t) is the average normalized cell index value of the reference
wells minus the Average Cell Index of the matching effectors used in the reference at time t. If
target alone is used as reference, there is no subtraction of AvgEffR_Sub_t168.

To add a qualitative element to our ADCC experiments and visually monitor the ADCC
responses of MNCs against different target cells, we also used the ImageXpress® Pico system
(Molecular devices, San Jose, CA). For this assay, we chose two cell lines positive for TK1 on
the cell membrane, the MDA-MB-231 and the HT-29 cell lines. To allow the
ImageXpress® Pico system to count individual cells, the cells were engineered with the
IncuCyte® Nuclight Green Lentivirus reagent (Sartorius, Gotinga, Germany) to express nuclear
restricted green fluorescent protein (Nuc-GFP). Cells were seeded at the same density described
above and grown overnight under controlled environmental conditions (37 °C, 5% CO2).
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Effector cells and anti-TK1 antibodies were then added to the target cells and the target cells
were counted each hr. for 48–72 hr. Normalized GFP cell count was compared between treated
and untreated cells. Antibody isotype controls were included as negative controls.

Statistical analysis
All the statistical analyses were performed using GraphPad Prism software (GraphPad,
San Diego, CA). For the analysis of the dose–response curves from the indirect ELISAs, the data
were log-transformed and analyzed with a 4-parameter non-linear regression analysis with a 95%
confidence interval (CI). The slope, the R square, and standard deviation of the residuals were
calculated. A test for goodness of fit, replicates test for lack of fit and test for homoscedasticity
were performed. For ADCC experiments involving dose–response curves, two-way repeated
measures ANOVA analyses were performed to compare different treatments during a coursetime. Analysis of multiple comparisons was performed comparing the mean of each treatment
with every other treatment mean. Correction of multiple comparisons was done with the Tukey
test. For cytolysis experiments, isotype control vs treatment group were compared using multiple
two tailed T-tests. Non-consistent standard deviation was assumed.

Results
Production and validation of recombinant human TK1

About 2 mg/ml of soluble protein was obtained from a 500 ml liquid culture. In-house
produced TK1 in yeast was then validated with Western blot using commercially outsourced
TK1 (< 80% pure) produced by Genscript in an E. coli expression system as positive control. A
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band of 25 kDa was be observed in both TK1 sources, commercially outsourced (bacteria) and
in-house produced (yeast) (Additional file 2-1) TK1 was detected with the anti-TK1antibody
ab91651, thus, validating our TK1 production process. In addition, a 50 kDa dimer band was
observed in the TK1 produced in our yeast expression system, showing the ability of our inhouse TK1 to properly fold and make TK1 complexes.

Selection of targetable regions in the active form of TK1

To identify regions specific for human TK1, alignments of the human TK1 sequence with
those of mice, dog and rabbit showed conserved and variable regions among species. However,
the epitopes of our interest were localized in the most variable regions of the TK1 human
sequence when compared with the other species (Fig. 2-1A). The similarity of the human TK1
sequence to other species is shown in Table 2-1. Six different epitopes across the TK1 molecule
were chosen for antibody generation (Table 2-2). The epitopes covered accessible regions in the
tetrameric form of the human TK1 isoform 1, from the N-terminus to the C-terminus (Fig. 2-1B).
BLAST results showed 100% coverage and identity for most of the epitopes’ hits specific for
TK1 protein with E values ranging from 10−5 to 10−15. We set an E value of 1e−6 as a tolerance
value for all the hits the epitopes had as recommended by the NCBI BLAST QuickStart
tutorial169. We did not see any non-TK1 related hits equal or below the cut-off value from the six
epitope sequences. Thus, the epitope sequences seemed to be unique to the human TK1, and no
significant similarities with other human proteins were found.
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Figure 2-1. Alignment of the amino acid sequences of thymidine kinase 1 from 4 different species, Canis lupus
familiaris, Oryctolagus cuniculus, Mus musculus and Homo sapiens. A, The conserved regions are highlighted and
the differences between species are shown in the identity top bar. TK1 epitopes are annotated in yellow. B, The
tetrameric form of TK1 was 3D modeled using the PyMOL software and the 1XBT crystal structure from the NCBI
protein data bank. The Peptide sequences utilized in the generation of monoclonal antibodies were highlighted in
red. The epitopes selected for antibody generation were all peptide sequences that were exposed and hypothetically
accessible to antibody binding. Epitope 6 is localized at the end of the C-terminus of the TK1 molecule but not
visible in the available crystal structures of TK1.

Table 2-1. Percentage of similarity between the TK1 sequences of different animal species.
O. cuniculus C. lupus M. musculus H. sapiens
O. cuniculus

85.54

C. lupus

85.54

M. musculus

86.27

83.47

H. sapiens

91.03

88.84

86.27

91.03

83.47

88.84
86.32

86.32

43

Table 2-2. The amino acid sequences and regions of the selected TK1 epitopes.
Epitope Sequence

Region

1

CYAKDTRYSSSFCTHDRNTME 55-74

2

MEALPACLLRDVAQEALGVC

73-91

3

CPDIVEFCEAMANAGK

103-117

4

CAYTKRLGTEKEVEV

161-174

5

CASGQPAGPDNKENCPVPGKP

193-212

6

KPGEAVAARKLFAPQQILQC

211-230

Validation of TK1 antibodies through western blotting

An initial screening using supernatants from the hybridomas clones was conducted to
identify antibody candidates. After this initial screening, a panel of 17 hybridoma clones was
selected for antibody production. To determine if these antibodies had the capacity to bind
human TK1 protein, we first performed western blotting with purified recombinant TK1 from
our yeast expression system and compared each of the antibodies with the commercial TK1
antibody Abcam (91651). The results showed that all antibodies except 10H2, 6A11, and 8F12
showed binding to the recombinant purified TK1 protein (Fig. 2-2A). It is known that TK1 exists
in multiple forms such as the monomeric, dimeric, and tetrameric form. We found that antibodies
4G10, 10E8, 6E10, 7D1, 8G2, 2E8 and 9A9 were able to bind multiple forms of TK1, including
the dimer and tetramer. In addition, the majority of the antibodies demonstrated ability to detect
TK1 in the serum of cancer patients (a representative sample using serum from a stage IV lung
cancer patient is shown in Fig. 2-2B). Although the antibodies mainly detected the dimeric form
of TK1 in serum, we observed that antibodies 4G10, 3G7, and 3B4 were able to detect the TK1
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monomeric form while the antibodies 5F7G11 and 2E8 seemed to detect a broader range of TK1
complexes from 25 kDa to 100 kDa or larger forms.

Figure 2-2. Western blot analysis of the generated antibodies for all 6 epitopes. The antibodies’ capacity to detect
human TK1 was tested. A, An amount of 0.5 μg of recombinant human TK1 was loaded in an SDS-PAGE and
transferred to nitrocellulose membranes. B, An amount of 20 μg of serum from a stage IV lung cancer patient was
loaded in each lane. The membranes were probed with the custom TK1 antibodies and compared with a commercial
TK1 antibody. For serum, a transferring antibody was included as a serum loading control and to test serum
integrity.

Antibody validation with a siRNA TK1 knockdown

After having confirmed the binding of the custom antibodies to recombinant TK1 and
TK1 in human serum samples, we decided to validate the specificity of six antibodies by
silencing the expression of TK1 using TK1 siRNA. In order to do that, we first tested if we were
able to successfully knockdown TK1 in the breast cancer cell line MDA-MB-231. We observed
a significant reduction in the expression of TK1 in the cells treated with the TK1 siRNA, while
expression of TK1 using GAPDH and the non-specific siRNAs was significantly higher.
Similarly, the cells treated with GAPDH siRNA showed a decrease of GAPDH expression
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according to Western blot analysis. GAPDH expression was not affected by TK1 siRNA or the
negative siRNA control (Fig.2-3A).

Figure 2-3. Validation of the custom anti-TK1 antibodies with a TK1 siRNA knockdown experiment in MDA-MB231 cells. A, GAPDH positive, SiRNA negative controls and TK1 siRNA s14160 were tested with commercial
anti GAPDH and anti TK1 antibodies. B, Validation of 6 custom TK1 antibodies with Western blot analyzing cell
lysates from siRNA negative control and TK1 siRNA treated MDA-MB-231 cells. C, Normalized TK1 expression
in reference to GAPDH and comparison of expression levels between cells treated with TK1 siRNA and untreated.

Six different antibodies against the six different TK1 epitopes were tested including
antibodies: 10E8 (Epitope 1), 10H2 (Epitope 2), 3B4 (Epitope 3), 5F7G11 (Epitope 4), 2E8
(Epitope5) and 3B2E11 (Epitope 6). Each antibody was tested using cell lysate from cells treated
with a negative siRNA control compared with a cell lysate from cells that were treated with TK1
siRNA. A significant reduction in the detection of TK1 was noticed with antibodies 10E8, 8G2,
3B4, 2E8 and 3B2E11. This difference was particularly pronounced with antibody 3B2E11,
which is the most sensitive antibody clone. No difference in the TK1 expression between cell
lysates was observed with antibody 5F7G11 (Fig. 2-3B, C). We observed that the main forms of
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TK1 present in cell lysate were the dimeric and the tetrameric forms. In the case of antibodies
10E8, 8G2 and 3B4, we could also observe TK1 forms of high molecular weight around or
above 200 kDa. Such bands were not detectable in cell lysates of siRNA TK1 treated cells.
While antibodies 10E8, 8G2 and 3B4 were able to detect multiple forms of TK1 in cell lysates,
antibodies 2E8 and 3B2E11 detected only tetrameric and monomeric forms, respectively.

Novel anti-TK1 antibodies detect TK1 surface expression in lung, breast, colon and prostate
cancer cells but not on normal MNCs

During flow cytometry experiments, we found that several of the anti-TK1 antibodies
were able to bind to membrane-associated TK1 across four different cancer cell lines (Additional
files 2-2 to 2-6). In the case of NCI-H460 cells, which had the highest TK1 levels, at least 1
antibody from each of the six TK1 epitopes show binding to membrane associated TK1.
Although in this cancer line, TK1 was targetable with all six epitopes, only epitope three seemed
to be targetable on the cell membrane of all the cancer cell lines. Moreover, the expression levels
of membrane associated TK1 (mTK1) changed depending on the cancer cell type. The maximum
number of cells positive for membrane associated TK1 was 95.6% for NCI-H460, 72.2% for
PC3, 62.4% for HT-29 and 49.1% for MDA-MB-231 cells. Two of the custom antibodies, 3B4
and 5F7G11 showed consistent binding to MDA-MB-231 (breast) and PC3 (prostate) cancer cell
lines, although antibody 5F7G11 showed low affinity for TK1 in indirect ELISA (Fig. 2-5). This
antibody also showed low specificity in antibody validation with an siRNA TK1 knockdown.
Thus, we excluded this antibody as a candidate for the immunotargeting of TK1. In the case of
the HT-29 (colon) cells, the antibodies with the highest binding for TK1 on the cell membrane
were 10E8, 7H2 and 3B4. In general, these four antibodies, 10E8, 3B4, 8G2 and 7H2 showed
47

similar or even higher binding levels compared to antibody ab91651 and were selected as
candidates to be used in ADCC experiments (Fig. 2-7). None of the custom antibodies mentioned
above showed significant binding to normal MNC. In the case of antibody 3B2E11 that showed
binding to H460 and PC3 cells, we decided not to use it as candidate for ADCC experiments, due
to its rat isotype. In multiple times, we observed that our Rat isotype control bound to PC3 cells
at similar levels as the antibody 5F7G11 which was generated in rat. Although this happened
only in PC3 cells, this antibody was excluded from our subsequent antibody-dependent cellmediated cytotoxicity (ADCC) experiments.
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Figure 2-7. Detection of TK1 surface expression through flow cytometry. Four different cancer cell lines expressing
membrane associated TK1 were stained with the custom TK1 antibodies. The binding capacities of the custom
antibodies were compared to a commercial TK1 antibody. A, The average percentage value of positive cells to TK1
from three independent flow cytometry runs across 4 cancer cell types, with lung cancer cells expressing the
maximum percentage (95.6%) followed by prostate (72.2%), colon (62.4%) and breast (49.1%). B, Clones 3B4,
8G2, 10E8 and 7H2 showed consistent binding for detection of TK1 surface expression in lung, prostate, breast and
colon cancer cell lines. In the case of H460 cells, which had the highest expression levels of TK1 on the cell
membrane, antibodies from epitope 1 and 6 showed binding consistently. Although 5F7G11 did not show high
specificity to TK1 when tested with a TK1 knockdown, the antibody showed consistent binding to the surface of all
cancer cell lines analyzed. In addition, antibody 8F12 showed consistent binding too but did not produce any signal
in indirect ELISA.
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Antibody validation through ELISA, targeting of different TK1 regions and sensitivity of the
antibodies

To find the most sensitive antibodies for the detection of TK1, each of the antibodies was
first individually tested by indirect ELISA using a dose–response curve (Fig. 2-4). The curves
were then analyzed with a 4-parameter non-linear regression and the limit of detection (LOD) of
each antibody was determined. From the 17 antibodies 13 fit the shape of a sigmoidal curve and
passed the goodness of fit test. The R squared values ranged from 0.9696 to 0.9989. For the
clone 9A9, we could see the bottom and the steepest part of the curve, but not the top plateau
region. This was due to the available range of the TK1 dilutions. However, a slope could be
calculated from the linear portion of the curve. Antibody clones 6A11 and ID3G4 did not
develop a detectable signal in ELISA. Thus, these clones were excluded from further testing. For
15 of the 17 TK1 antibodies, the inter-assay CV% was between 1.52 and 17.32, while the intraassay CV% was between 0.45 and 11.40.

Figure 2-4. Calibration curves of indirect ELISAs. Each antibody’s binding capacity to TK1 was tested in indirect
ELISA. A 4-point non-linear regression analysis was performed for each dose–response curve. Antibody curves
have been grouped according to their epitope specificity.

50

The limit of detection was calculated for each of the antibodies as previously described in
the methods section. The interpolated values, standard deviations and percentage of the inter and
intra coefficient of variance for each antibody are shown in Table 2-3. From the indirect ELISA,
we found that the most sensitive antibodies were produced by the clones 3B2E11, 9C10, 7H2,
2E8, and 1B12, with clone 3B2E11 producing the most sensitive antibody, having a LOD
between 8.87 and 12.58 pg/ml (Table 2-3 and Fig 2-5). These antibodies were able to detect
concentrations of TK1 in the picomolar range, thus making them candidates for clinical and
therapeutic applications.

Table 2-3. Sensitivity of the TK1 antibodies. The LOD values are expressed as mean values from
two independent immunoassays. Precision and uncertainty are reflected in the coefficient of
variance between assays. The most sensitive antibodies are marked with stars.
Mean
Clone

ID

Isotype

Host

LOD
pg/ml

SD±

Inter CV

Intra CV

LOD

%

%

4G10

1-1

IgG2a, κ

Ms

146.40

33.96

16.4

5.72

*10E8

1-2

IgG1, κ

Ms

44.67

4.33

9.69

11.40

*7H2

1-7

IgG1, κ

Ms

19.79

0.55

2.78

9.71

7D1

1-9

IgG1, κ

Ms

94.03

12.86

13.68

8.41

*1B12

2-1

IgG2a, κ

Ms

38.76

4.84

12.5

4.57

3G7

2-6

IgG2a, κ

Ms

125.96

21.0

16.67

1.09

10H2

2-15

IgG2a, κ

Ms

56.50

15.96

20.3

8.2
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*8G2

2-17

IgG2b, λ

Ms

72.87

4.83

1.62

8.38

*9C10

2-19

IgG2a, κ

Ms

11.01

0.67

6.1

4.0

*3B4

3-5

IgG2b, κ

Ms

66.90

3.5

5.33

0.45

6A11

3-6

IgG1, κ

Ms

NA

NA

NA

NA

8F12

3-10

IgG1, κ

Ms

101.00

16

15.84

2.5

5F7G11

4-2

IgG2a, λ

Rat

1376.58

153.42

11.14

0.71

*2E8

5-1

IgG2b, λ

Ms

33.10

0.50

1.52

1.5

9A9

5-10

IgG2b, κ

Ms

12006.28

244.36

2.04

1.76

*3B2E11

6-1

IgG2a, λ

Rat

10.73

1.85

17.32

6.58

1D3G4

6-2

IgG2a, λ

Rat

NA

NA

NA

NA
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Figure 2-5. Comparison of antibody sensitivities. The LOD values of each antibody were plotted and compared. The
most sensitive clones were 3B2E11, 9C10, 7H2, 2E8, and 1B12

In order to test the potential of the custom antibodies as diagnostic tools, we tested
different antibody pairs in sandwich ELISA. The detection antibodies were biotinylated to
facilitate the union of streptavidin-HRP protein. The antibody pairs that showed consistent
results were 7H2 as capture (C) and 3B2E11 as detection (D), 10E8 (C) and 3B2E11 (D) and
2E8 (C) and 3B2E11 (D) (Fig. 2-6A). The sensitivity of the antibody pairs ranged from 0.12 to
0.04 ng/ml. The signal generated at the LOD of each antibody was at least three standard
deviations far from the blanks (Fig. 2-6B).
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Figure 2-6. Evaluation of three antibody pairs for TK1 detection in sandwich ELISA. A, Dose response curves and
4-point non-linear regression analysis of three antibody pairs. B, The signal obtained from TK1 detection in serial
dilutions with three antibody pairs is proportional to the concentration of antigen. C, Optimization of capture and
detection antibodies concentration ratios. D, Spiking recovery assay. Assessment of the interference of human serum
with the antibodies’ capacity to detect a known concentration of TK1. Recovery was around 100% with 10% serum
dilution. E, Specificity of the immunoassay to TK1. Using cell lysate from a high expressing TK1 cancer cell line
and lysate from cells treated with siRNA TK1, the specificity of the immunoassay was evaluated. Signal from the
siRNA TK1 knockdown cell lysate was significantly lower than the untreated cell lysate

To evaluate the effect that human serum could have on the antibodies’ detection capacity,
we performed a spiking recovery assay to determine the ability of these three antibody pairs to
detect TK1 in human serum. A 10% serum dilution was spiked with a known amount of TK1
(10 ng/ml). We then determined how much of this added TK1 could be detected, expressed as a
recovery percentage. For the pairs 10E8 (C) and 3B2E11 (D), 7H2 (C) and 3B2E11 (D) and 2E8
(C) and 3B2E11 (D), the recovery percentages were 96%, 113% and 91%, respectively (Fig 26D). To further test the specificity of the antibody pairs, we choose the antibody pair 2E8 (C)
and 3B2E11 (D) and compared the signal generated by this pair from a cell lysate positive for
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TK1 and a cell lysate from cells treated with siRNA TK1. Both cell lysates were diluted to the
same protein concentration. As an additional control, we included spiked serum with a known
concentration of TK1. We observed that there was a significant difference in the signal (about
sixfold) obtained between normal cell lysate and cell lysate from cells treated with TK1 (Fig. 26E).
TK1 can be detected in plasma membrane protein extracts from cancer cells, but not in extracts
from normal cells

We found that TK1 was present in the plasma membrane protein fraction of H460 cells,
but we could not detect TK1 in the plasma membrane fraction of normal MNC cells. We did not
see signal coming from the GAPDH negative control, thus indicating low contamination levels
of cytosolic proteins in the plasma membrane protein extract. The plasma membrane protein
fractions were positive for Na/K ATPase, which is present on the cell membrane (Fig. 2-8).

Figure 2-8. Representative western blot image for detection of membrane-associated TK1 on NCI-H460 cells
Levels in plasma membrane protein extracts from NCI-H460 and healthy mono nuclear cells were compared on
Western blot. A, Plasma membrane protein extract from NCI-H460cells had high levels of membrane-associated
TK1. B, Membrane associated TK1 was not detected in plasma membrane proteins extracts from healthy MNCs.

Anti-TK1 monoclonal antibodies are able to elicit ADCC responses
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Since membrane expression of TK1 was detected with several of the anti-TK1 antibodies,
we decided to test their potential to target TK1 and elicit an in vitro ADCC response against
cancer cells. We selected the antibodies 10E8, 8G2 and 3B4 for their specificity and capacity to
detect membrane expression of TK1. For these experiments, two real-time cell analysis systems
were used. For our initial ADCC experiments involving A549 cells, we used the ExCELLigence
platform. For our subsequent ADCC experiments we used the ImageXpress®Pico system, which
allowed us to incorporate cell imaging along with our cell measurements. The A549 (lung), the
MDA-MB-231 (breast) and the HT-29 (colon) cell lines used in these experiments were
previously screened to confirm the expression of membrane associated TK1 (Fig.2-9).

Figure 2-9. Expression of TK1 on A549 cells. A, Surface expression of TK1 on A549 cells detected by flow
cytometry with TK1 antibody ab91651. B, Optimization of effector and target cell ratios for ADCC assays using the
ExCELLigence platform. Four different E:T ratios were tested. E:T ratios close to 1:1 showed reduced non-specific
cell killing by MNCs. Eight thousand target cells (A549) were used in all wells

In order to find the right effector cell/target cell ratio, we first optimized the amount of
effector (E) and target (T) cells without an antibody present. In the case of the ExCELLigence
system, we found that E:T ratios of 1.25:1 and 0.625:1 produced less background of non-specific
cell killing (Fig. 2-9B). After finding the optimum E:T ratios, we tested different concentrations
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of the custom TK1 antibodies 3B4 and 8G2. The purpose of this was to find the lowest
concentration of antibody at which a significant ADCC response was produced, in comparison to
control groups. In the case of the antibody 3B4 (isotype IgG2b), we found that concentrations of
5.0 and 7.5 μg/ml caused significant increases in cell killing of A549 cells by MNC, compared to
IgG2b isotype control (p = 0.0001) for both concentrations. In the case of the 8G2 (isotype
IgG2b) antibody, a concentration of 2.5 μg/ml was enough to elicit a response significantly
different from the IgG2b isotype controls (p = 0.0003). However, higher concentrations of 8G2
yielded significantly stronger ADCC responses (Fig. 2-10B). After adding the TK1 antibodies,
the maximum amount of specific cell killing induced by antibodies 3B4 and 8G2 was observed
at 36 h and 48 h (Fig. 2-10E, F). The normalized cell indexes of the target cells and effector cells
were not affected by the antibodies themselves. Once we found the minimum concentration of
antibody that was necessary to elicit a significant ADCC response, we proceeded to measure the
percentage of specific cytolysis. In the case of antibody 3B4, the maximum percent of cytolysis
was observed after 36 h of treatment, while for 8G2 antibody, this occurred at 48 hr. An increase
in specific cytolysis around 70% was observed with the antibody 8G2 (p = 0.001) while this
value was 60% with the antibody 3B4 (p = 0.0001) (Fig. 2-10C, D).
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Figure 2-10. ADCC assay using TK1-specific monoclonal antibodies 3B4 and 8G2. MNC and A549 cells were cocultured in the presence or absence of the TK1 monoclonal antibodies 3B4 and 8G2. A, On the left, a 3B4 antibody
concentration dose–response curve can be observed. The ADCC response started after 24 hr. of treatment. C and
E, A significant cytolysis percentage is observed at 36 hr. with a 7.5 μg/ml 3B4 antibody (p = 0.0001). Graph
B shows a dose-response curve for antibody 8G2. D and F, A significant increase in the cytolysis percentage
compared to the isotype controls (p = 0.0003) was observed at 48 hr. with a 2.5 μg/ml antibody concentration

For our subsequent ADCC experiments, we evaluated the ADCC response generated with
the antibodies 3B4 and 10E8 against breast and colon tumor cells using the ImageXpress® Pico
system. The cell lines MDA-MB-231 and HT-29 were previously engineered to express nucGFP, which allowed monitoring of cell death and proliferation. We found that a 5:1 E:T ratio
worked better for our GFP-based assays. A concentration of 5 μg/ml was enough to elicit an
ADCC response with antibody 10E8, while 7.5 μg/ml was utilized for antibody 3B4. A cytolysis
around 70% of the MDA-MB-231 cells was observed when antibody 3B4 was added (Fig. 258

11A). The ADCC response was significant when compared to the isotype control (p = 0.0172). In
the case of HT-29 cells, a cytolysis about 50% was observed using antibody 10E8 (p = 0.0216),
which was significantly different from the isotype control (Fig. 2-11B). Cell imaging revealed an
increased migration and clustering of MNCs around target cells when TK1 antibodies where
added. Cell killing was visually confirmed by the presence of apoptotic cells and a significant
reduction in the average fluorescence intensity of the target cells.

Figure 2-11. ADCC experiments on the MDA-MB231 breast cancer and the HT-29 colon cancer cell lines using the
ImageXpress® Pico real time cell imaging system.A, The ADCC response against MDA-MB231 cells by MNCs
using antibody 3B4. A significant decrease in the number of target cells was detected at 72 hr. compared to the
isotype control (p = 0.0172). B, The ADCC response against HT-29 cells by MNCs using antibody 10E8. A decrease
in the number of target cells of about 50% was detected at 48 hr. (p = 0.0216).
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Discussion

Scientific evidence points to TK1 is a suitable tumor biomarker for the early detection of
malignancy, tumor progression, prediction of recurrence and patient outcome54,170,171. However,
new evidence indicates an emerging role of TK1 as a possible tumor target. Previous findings
confirming the presence of cell membrane associated TK1 forms in tumor cells from patients and
recent studies reporting the targeting of TK1 expression inside cells, have strengthened the
clinical relevance of TK1 as a tumor target81,82. In this study, we have explored the targeting of
TK1 with monoclonal antibodies. To our knowledge, this is the first time that the targeting of
TK1 with monoclonal antibodies in lung, breast and colon cancer cells has been reported. In
addition, we have described the generation and characterization of a new panel of high-affinity
TK1 monoclonal antibodies, targeting six different epitopes, for the detection and
immunotargeting of cancer.

Our results found that TK1 could be potentially targeted with antibodies at 6 different
regions. In particular, antibodies against TK1 epitope two, five and six showed the highest
affinities (bellow 50 pg/ml) (Fig.2-5). Since these are regions that appear to be on the exterior of
the tetrameric form of TK1, antibodies may have easier access to these particular epitopes. In the
past, TK1 has primarily been targeted towards the C-terminus, and although there are some
commercial antibodies that target regions at the N-terminus, there is no available data indicating
that these antibodies can reliably detect TK1 in serum or membrane-associated TK1 forms. To
our knowledge, there is only one clinically tested TK1 immunoassay currently available and it
targets a region called XPA-210 towards the C-terminus172. Thus, the combination of antibodies
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targeting multiple regions of the TK1 molecule could help us increase our ability to target TK1
in cancer cells.
The potential of these antibodies to detect and target cancer cells was initially tested with
flow cytometry (Fig. 2-7). We found that the antibodies developed were able to detect membrane
TK1 expression in lung, breast, prostate and colon cancer cells. This may indicate the possibility
of targeting a broad spectrum of tumors. In addition, we found specific epitopes that seem to be
exposed in the membrane associated form of TK1. According to our flow cytometry data, the
regions of the membrane associated TK1 molecule that seem to be exposed were mainly epitope
two, three and four (Table 2-2). Epitope two, is an exposed ribbon in the tetrameric form of TK1
located towards the N-terminus while, epitope three is a ribbon towards the center of the
molecule. Epitope four contains a lasso and the active site of the molecule, suggesting that
membrane associated TK1 may keep kinase activity81. However, depending on which cancer cell
line was analyzed, we observed that other epitopes were exposed as well. This was the particular
case for H460 and HT-29 cells, where anti-TK1 antibodies for epitopes one and six showed
binding to the cell membrane, while these epitopes were not detectable in MB-MDA-231 cells
and PC3 cells. It is important to emphasize that NCI-H460 cells were the cells with the highest
levels of TK1 on the cell membrane. Thus, it is possible that the higher expression levels of
surface TK1 make these epitopes more accessible for antibodies. The absence of significant
binding of the anti-TK1 antibodies to normal cells confirms our previous reports that TK1
membrane expression may be restricted to malignancy. This was further confirmed by Western
blot analysis of membrane associated TK1 protein levels in NCI-H460 cells plasma membrane
protein extracts and plasma membrane protein extracts from normal MNCs (Fig. 2-8). This,
makes TK1 an immunotarget with low off-target effects that could be used for antibody-based or
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cell adoptive therapies such as chimeric antigen receptor (CAR) T cell therapy173. Furthermore,
if membrane expression of TK1 is restricted to malignant cells, then the detection of membrane
associated TK1 forms may be a hallmark linked to the development of particular cancers.

Although the role of TK1 as a tumor biomarker has extensively been studied, little has
been done to explore the potential of TK1 as a tumor target. Previous studies have suggested that
TK1 in malignant cells may be different than TK1 in normal cells. In fact, the targeting of
malignant forms of TK1 was suggested almost three decades ago by other research groups 150,151.
Due to their high specificity, monoclonal antibodies are ideal candidates for the specific targeting
of TK1 in cancer cells. In addition, we did not find any available studies about targeting TK1
with monoclonal antibodies particularly targeting its membrane associated forms in malignant
cells. Thus, our ADCC experiments were designed to explore this possibility.

During this study three of our custom TK1 antibodies, antibodies 10E8 (targets epitope
one), 8G2 (targets epitope 2) and 3B4 (targets epitope three) were selected for their specificity
and capacity to detect membrane associated TK1 on malignant cells. In this case, the anti-TK1
antibodies’ ability to elicit an ADCC response was measured. It is important to mention that even
though the commercial anti-TK1 antibody ab91651 could detect surface expression of TK1, its
particular rabbit isotype made it unsuitable for our ADCC experiments. We found a significant
increase in the cytolysis of lung, breast and colon cancer cells by MNC when the anti-TK1
antibodies were added in comparison to controls (Figs. 2-10 and 2-11), thus confirming previous
reports of the membrane expression of TK1 and opening the door for additional studies exploring
the targeting of TK1 in cancer cells.
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The mechanisms through which TK1 is expressed on the surface of cancer cells remains
unknown. However, there are some indications of its associations with the cell membrane. In the
past, other pyrimidine salvage pathway enzymes were found to be associated with the membrane
of cancer cells46. Other studies using yeast two-hybrid experiments have found TK1 interacting
with other membrane proteins such as SEZL6 that are upregulated in lung cancer cells174,175.
Therefore, the characterization of novel TK1 protein–protein interactions on the membrane of
cancer cells can possibly lead to the development of more specific targeted therapies. The dual
targeting of tumor antigens is a feasible strategy that has been tested before in cancer
immunotherapy176.

The experiments presented here provide early evidence that the targeting of membraneassociated TK1 with monoclonal antibodies may be a feasible approach for the treatment of
cancer. In addition, we have developed a novel panel of TK1 antibodies that may be useful for
TK1-based diagnostics. Future directions of this research will focus on the targeting of several
other cancer cell lines, in vivo ADCC experiments and the development of both antibody-based
and cell adoptive therapies targeting TK1.

Conclusions

The antibodies presented here had the ability to detect and quantify TK1 in the picomolar
range and potentially could allow us to measure TK1 levels in cancer patients. In addition, the
antibodies were able to detect multiple forms of TK1, including membrane-associated TK1 in
lung, breast, colon and prostate cancer cells. Thus, TK1 may be a tumor target that can be used
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for therapy in multiple solid malignancies. The increased cytolysis of A549, MDA-MB-231 and
HT-29 cells by MNCs in the presence of anti-TK1 monoclonal antibodies during the in vitro
ADCC experiments suggests that TK1 monoclonal antibodies have potential not only as
diagnostic tools, but also as immunotherapeutic agents for the treatment of cancer. Therefore, the
immunotargeting of TK1 may be a feasible approach for the elimination of cancer cells. The
exploration of TK1 as a tumor target may lead to the development of other TK1-based
immunotherapeutics.
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Supplementary figure 2-1

Supplementary figure 2-1. Production and validation of human recombinant TK1 in a yeast-based expression
system. The sequence of human TK1, transcript variant 1, (Accession No. NM_003258.5) was codon optimized to
be expressed in a Saccharomyces cerevisiae yeast strain with a REG-1 mutation. A 6xHis tag was added at the Cterminus to facilitate His-tag purification. The optimized TK1 sequence was synthesized and cloned into the pESCURA vector (Genscript, Piscataway, NJ) and was purified by affinity chromatography using NI-NTA-agarose beads
columns (Qiagen, Hilden, Germany). In-house produced TK1 was validated along with commercially outsourced
recombinant TK1 in Western blot using the anti-TK1 antibody ab91651 (Abcam, Cambridge, UK).

Supplementary figure 2-2

Supplementary figure 2-2. Flow cytometry analysis of NCI-H460 cells with the custom TK1 antibodies. See Table
2-3 to find the name of each clone associated with its respective ID.
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Supplementary figure 2-3

Supplementary figure 2-3. Flow cytometry analysis of MDA-231 cells with the custom TK1 antibodies.See Table 23 to find the name of each clone associated with its respective ID.
Supplementary figure 2-4

Supplementary figure 2-4. Flow cytometry analysis of PC3 cells with the custom TK1 antibodies.See Table 2-3 to
find the name of each clone associated with its respective ID.
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Supplementary figure 2-5

Supplementary figure 2-5. Flow cytometry analysis of HT-29 cells with the custom TK1 antibodies.See Table 2-3 to
find the name of each clone associated with its respective ID.
Supplementary figure 2-6

Supplementary figure 2-6. Flow cytometry analysis of normal MNC cells with the custom TK1 antibodies.See Table
2-3 to find the name of each clone associated with its respective ID.
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Abstract

Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good
prognostic capabilities for both hematological and solid malignancies. However, recent studies
targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a therapeutic
target. In order to examine the use of TK1 as a therapeutic target, it is necessary to develop
therapeutics specific for it. Single domain antibodies (sdAbs), represent an exciting approach for
the development of immunotherapeutics due to their cost-effective production and higher tumor
penetration than conventional antibodies. In this study, we isolated sdAb fragments specific to
human TK1 from a human sdAb library. A total of 400 sdAbs were screened through 5 rounds of
selection by monoclonal phage ELISA. The most sensitive sdAb fragments were selected as
candidates for preclinical testing. The sdAb fragments showed specificity for human TK1 in
phage ELISA, Western blot analysis and had an estimated limit of detection of 3.9 ng/ml for the
antibody fragments 4-H-TK1_A1 and 4-H-TK1_D1. The antibody fragments were successfully
expressed and used for detection of membrane associated TK1 (mTK1) through flow cytometry
on cancer cells [lung (~95%), colon (~87%), breast (~53%)] and healthy human mononuclear
cells (MNC). The most sensitive antibody fragments, 4-H-TK1_A1 and 4-H-TK1_D1 were fused
to an engineered IgG1 Fc fragment. When added to cancer cells expressing mTK1 co-cultured
with human MNCs, the anti-TK1-sdAb-IgG1_A1 and D1 were able to elicit a significant
antibody-dependent cell-mediated cytotoxicity (ADCC) response against lung cancer cells
compared to isotype controls (P<0.0267 and P<0.0265, respectively). To our knowledge this is
the first time that the isolation and evaluation of human anti-TK1 single domain antibodies using
phage display technology has been reported. The antibody fragments isolated here may represent
a valuable resource for the detection and the targeting of TK1 on tumor cells.
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Introduction
Efficient DNA repair and synthesis requires a balanced supply of nucleotides and
coordination of the metabolic pathways utilized for their production 177. In order to sustain
proliferation, malignant cells have significant alterations in the activity levels of several of their
nucleotide synthesis enzymes 20,178,179. These alterations, particularly in the pyrimidine salvage
pathway, can lead to an imbalance in the cell’s nucleotide pools which could lead to error prone
DNA replication and genome instability, a hallmark of cancer 134,180,181. Thymidine Kinase 1
(TK1) is a pyrimidine salvage pathway enzyme that catalyzes the phosphorylation of thymidine
to thymidine monophosphate 182. In healthy cells, TK1 is only elevated during the S phase, but
low or absent during other cell cycle stages 183,184. However, in malignant cells TK1 expression
levels are upregulated and the enzyme seems to lose its normal cell cycle regulation control
elements 51. Increased levels of TK1 in both tumors and serum are associated with disease stage
and, as cancer progresses, serum TK1 levels increase with disease stage 146,185,186. During the last
3 decades scientific evidence has shown that TK1 levels in the serum of cancer patients can be
used as a biomarker for early cancer detection 137,187. As TK1 levels in serum are correlated with
tumor progression, patient response and cancer recurrence, TK1 has also been proposed as a
suitable tumor biomarker for the continued monitoring of patients 139,140,142,145,188.

While the usefulness of TK1 as a tumor biomarker has been the main focus of many
studies, in recent years the interest in using TK1 as a therapeutic target for multiple cancers has
gradually increased 153. In a study conducted by Malvi et al., the silencing of TK1 in lung
adenocarcinoma (LUAD) cell lines inhibited the cell growth, migration and invasion capacities
of LUAD cells both in vitro and in vivo 189. Similarly, another study showed that targeting of
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TK1 through genetic knockdown significantly reduced cell proliferation of pancreatic ductal 151.
In addition, it has been reported, that some forms of TK1 seem to be able to associate to the cell
membrane of several cancer cell types, including leukemia, breast, lung and colon tumor cells
possibly through protein-protein interaction or transitory membrane localization through
exosomes 81,82,190. Moreover, early experimental data has shown that membrane associated TK1
(mTK1) in lung, colon and breast cancer cells could be targeted using monoclonal antibodies.
However, the study was limited to some extent because the antibodies used were produced in
mice and humanized antibodies are still required to better evaluate potential therapeutic use in
humans 191. This evidence together suggests that the targeting of TK1 both inside the cell and its
mTK1 form could be possible approaches for the development of novel cancer therapies.
Therefore, the generation of therapeutics specific for TK1 could enable us to explore the
potential of TK1 as a tumor target.

Monoclonal antibodies (mAbs) are suitable candidates for the development of cancer
therapies due to their high specificity and affinity for their molecule targets 192. The majority of
current therapeutic antibodies have been produced with hybridoma technology or in transgenic
mice, these approaches require the use of special animals, time consuming protocols and
humanization or reformatting through complicated techniques such as CDR engraftment before
any therapeutic use is possible 193,194. Recently, phage display technology has been incorporated
in the production pipeline of therapeutic antibodies by many pharmaceutical companies 195,196.
This technology offers the possibility to explore vast human antibody libraries in a relatively
short period of time compared to hybridoma technology and does not require animals and can
isolate antibodies against weakly immunogenic antigens 197. In addition, the antibody fragments
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can be isolated in convenient formats that facilitate further modifications for therapeutic
applications 198,199. The use of phage display technology to obtain single domain antibody
fragments (sdAbs), also called nanobodies, against TK1 is a convenient and appealing approach
to isolate and develop biopharmaceuticals specific for the targeting of TK1. In this study we
isolated human antibody fragments against the tumor proliferation biomarker TK1 from a sdAb
library. The antibody fragments were evaluated for their capacity to bind and detect TK1 in
monoclonal phage ELISAs, Western blot and flow cytometry. The antibody fragments were then
incorporated into engineered IgG1 constructs and tested for their capacity to target TK1 on
malignant cells and elicit an ADCC response from human MNCs against cancer cells. We
hypothesize that engineered single domain antibodies (sdAb) specific for TK1 can efficiently
target tumor cells expressing high levels of TK1. Thus, the use of human sdAb molecules
targeting TK1 may enable us to better explore the potential of TK1 as a tumor target in
proliferating malignant cells.

Materials and methods
Isolation of anti-TK1 sdAb fragments through phage display
A phage display library of human single domain antibodies developed by Dr. Daniel
Christ at the MRC laboratory of molecular biology was used to select high affinity anti-TK1
sdAbs (Source Bioscience, Cambridge, U.K) as previously described 200. The full repertoire of
sdAbs was contained within a single human VH framework (V3-23/D47) fused to the gene III
protein of the M13 filamentous phage. The sdAb library was constructed into the pR2 (MYC
VSV-G tag) plasmid and had a diversity of 3x10 fragments. Each sdAb fragment contained three
9

diversified complementary regions (CDR1, CDR2 and CDR3). Ubiquitin and Galactosidase sub
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libraries were also included as positive controls and run before using the dAb library to test the
viability of the components of the library and verify that the selection process and testing of the
sdAbs would be performed correctly.

To initially amplify the full repertoire of sdAbs, one aliquot of the sdAb library, which
was contained in E. coli TG1 bacteria, was grown in 500 ml of 2xTY media supplemented with
4% glucose and 100 μg/ml of ampicillin until the culture reached an OD600 of 0.5. An amount of
2x1012 KM13 helper phages were added to 500 ml of each TG1 bacteria culture, and the culture
was incubated for 1 hour at 37 ºC without agitation. After infection, the media was replaced with
2xTY media containing 0.1 % glucose, 100 μg/ml of ampicillin and 75 μg/ml of kanamycin and
the library was grown for 24 hours at 25 ºC on a shaker at 250 rpm. The phages displaying the
sdAb fragments were then purified using polyethylene glycol 6000 (PEG) solution (Millipore
SIGMA, St Louis, MO, USA). The purified phages were then quantified by infecting TG1
bacteria with serial dilutions of the phage and plating the infected TG1 on TYE amp plates. Fulllength human recombinant TK1 (>80% pure) produced in E coli (Genscript, Piscataway, NJ) was
diluted in phosphate buffered saline (PBS) buffer to a 50,000 ng/ml concentration. TK1 was then
immobilized on Maxisorp plates (ThermoFisher Scientific, Waltham, MA) by adding 100 ul of
above TK1 solution and incubating them at 4 ºC overnight. The plates were then blocked with
5% milk PBS buffer (MPBS) for 45 minutes at room temperature on a shaker followed by 15
minutes at 37 ⁰ C. The plates were then washed 3 times with PBS. Approximately 5x1010 phages
displaying the full repertoire of sdAbs, were applied to each well that had been coated with TK1.
To increase the surface area available for capture of the whole repertoire of the sdAb library,
each phage dilution was added to four wells. Phages were allowed to bind for 1 hour at room
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temperature with moderate shaking. After incubation, the wells were washed 15 times with PBST buffer (0.1% Tween) and 2 times with PBS buffer. The phage-sdAbs that remained attached
were then eluted by adding 100 μl of a 0.1 mg/ml trypsin-TBSC buffer solution (Millipore
SIGMA, St Louis, MO, USA) and incubation for 1 hour at room temperature with moderate
shaking. The eluted phages were then recovered and used to infect a 30 ml TG1 bacteria culture
0.5 OD600. The infected culture was then incubated for 1 hour at 37 ⁰C without shaking. After
infection, the TG1 bacteria were harvested and resuspended in 1 ml of 2xTY media. The cells
were then plated on TYE, 4% glucose plates with ampicillin (100 μg/ml). The next day, colonies
were scraped off and grown in 500 ml of 2xTY until the cultures reached at 0.5 OD600. The
cultures were then infected with 1x1012 KM13 phages and grown at 25 ⁰C for 24 hours on a
shaker at 250 rpm. After incubating for 24 hours, the phage-antibody sub library was purified
using PEG 6000 and the phage titer was determined for both the eluted phages and the purified
phages. This process of selection was repeated 5 times. To eliminate antibodies that could
possibly bind to the 6xHis-tag in TK1, the last two rounds of selection were done using TK1
produced in HEK 293expi cells without a 6xHis-tag (Origene, Rockville, Maryland, USA).

Polyclonal and monoclonal phage ELISAs
To monitor the increase in the overall number of TK1 binders between rounds of
selection the isolated phages from each round of selection were screened using a polyclonal
phage ELISA. For the polyclonal phage ELISA 96-well Costar plates (Corning, NY, USA) were
coated with 100 μl of serial dilutions of TK1 (50,000 ng/ml-400 ng/ml) in duplicates. Uncoated
wells (without antigen) were included as blanks in each ELISA. After the wells were coated, the
plates were incubated overnight at 4°C with gentle agitation. After incubating, the plates were
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washed 3 times with PBS buffer and blocked with 240 μl of MPBS for 45 minutes at room
temperature followed by 15 minutes at 37°C. Wells were washed 3 times with PBS and purified
phages diluted in MPBS (1:1 ratio) were added into each well. The plates were incubated for 1
hour at room temperature with gentle agitation. After incubating the plates were washed with
PBS-T five times and 100 μl of Horse Radish Peroxidase (HRP) conjugated anti-M13 antibody
solution (1:2,000 dilution in MPBS) was added into each well. Following addition of the HRP
conjugated antibody, 100 μl of Tetramethyl Benzidine (TMB) substrate (ThermoFisher
scientific, Waltham, MA, USA) was added into each well and the color was allowed to develop
for 30 minutes. The reaction was stopped with 50 μl of 1M sulfuric acid, and the absorbance
values were measured using a Synergy HT Microplate Reader (Bio-Tek Winooski, VT) at 450
nm and 650 nm.

Eighty individual clones were tested using monoclonal phage ELISA following every
round of selection (biopans). After each biopan and before scraping off the colonies, eighty
clones were picked and grown overnight at 37°C in 200 μl of 2xTY media supplemented with
4% glucose and ampicillin (100 μl/ml). Culture dilutions (1:40) from the overnight cultures were
made by diluting 5 μl of the overnight culture in 200 μl of 2xTY 4% glucose and ampicillin and
grown at 37°C for three hours. After reaching a 0.5 OD , 50 μl of 2xTY containing 4 x 10
600

8

KM13 helper phages were added into each well to produce phage-sdAb fragments. The infected
cultures were incubated at 37°C for one hour without shaking and the media was changed with
200 μl of 2xTY with 0.1% glucose, ampicillin (100 μg/ml), and kanamycin (75 μg/ml). Cultures
were grown at 25°C for 24 hours at 250 rpm. After 24 hours the plates were centrifuged at 3200
x g for 10 minutes and the supernatants were recovered from each well. Each supernatant was
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then mixed with MPBS in 1:1 ratio. To test each clone for its capacity to bind to TK1, 96 well
plates were coated with 100 μl of a 10,000 ng/ml solution of TK1 per well as previously
described. The same protocol as described for the polyclonal phage ELISA was used for the
monoclonal phage ELISA.

Detection of phage-sdAbs by dot blot
Dot blot was used to confirm the expression of sdAb fragments in TG1 supernatants.
After recovering supernatants containing phage-sdAb fragments, 2-3 μl of each supernatant
containing the phage-sdAbs was immobilized on a nitrocellulose membrane (BIO-RAD,
Hercules, CA). The membrane was then blocked with 5% MPBS for 1 hour at room temperature
on a shaker. The membrane was then incubated with a 1:20,000 anti-VSV-G-HRP antibody
solution at 4 ºC overnight with moderate shaking. The next day, the membrane was washed 3
times with 240 μl of PBS-T for 5 minutes. After the membranes were washed, 2 ml of enhanced
chemiluminescence substrate (Advansta Corporation, San Jose, CA) was added so that the
membrane was completely covered. The membranes were incubated for 2 minutes, and the
excess of reagent was poured off. Membranes were covered in plastic wrap and light sensitive
films were placed on the membranes for different exposure times and measured using an imaging
developer.

Sensitivity of TK1 specific antibody fragments
The sensitivities of the TK1 sdAbs were determined using dose-response curves and
monoclonal phage ELISA. Briefly, Costar 96-well plates (Corning) were coated with serial
dilutions of TK1 in duplicate overnight at 4⁰C with gentile agitation. The dilutions ranged from
76

23,600 ng/ml-23 ng/ml for E-TK1 and 500 ng/ml-3.9 ng/ml for H-TK1. The next day, plates
were blocked with 240 μl of MPBS/well for 45 minutes at room temperature and 15 minutes at
37°C. After blocking, the wells were washed three times with PBS and 100 μl of a 1:1 dilution of
phage supernatant in MPBS was added into each well. Subsequent steps in the ELISA were
carried out as previously described. The curves were then analyzed using a four-point parameter
logistic curve and the limit of detection of each sdAb fragment was determined. A signal that
was at least three standard deviations away from the signal of the blank was used as the limit of
detection, as previously described 201. The sensitivities of the clones were then compared.

Validation with a TK1 siRNA and non-specific binding controls
In order to confirm specific binding to TK1, individual clones were screened against
lysate from a siRNA TK1 knockdown cell line and compared to wild type cell lysate. The TK1
knock down cell lysate was prepared as previously described 191. TK1 forms produced in
bacterial, yeast, and mammalian expression systems were used as positive controls and uncoated
wells were used as negative controls. The monoclonal phage ELISA was performed as described
above.

Sequencing Analysis of sdAb fragments
Plasmids were isolated from the clones that showed the highest affinity for TK1 using the
PureYield Plasmid Miniprep system (Promega). Samples were prepared for sequencing using the
primer (5’ CCCTCATAGTTAGCGTAACGA 3’) and the universal M13 reverse primer (5’
CAGGAAACAGCTATGAC 3’). Sequencing data was analyzed using Genious prime software
163

.
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Anti-TK1-sdAbs protein modeling and docking analysis of sdAb-TK1complexes
The structures of the anti-TK1-sdAb fragments were analyzed using the GalaxyWEB
TBM web server. The most stable structures of each anti-TK1 sdAb fragment were analyzed
using the Visual Molecular Dynamics (VMD) software developed by the computer science and
biophysics department of the University of Illinois 202. The CDR regions were mapped by
analyzing the deduced amino acid sequences of each anti-TK1-sdAb fragment in the IgG Blast
tool from NCBI. The sequences of the anti-TK1-sdAb fragments were aligned using Genious
prime software. In silico analysis of the interaction between the anti-TK1-sdAb fragments and
the crystal structure of TK1 was performed using the high ambiguity driven protein-protein
docking (HADDOCK) web server 203. Visualization of the anti-TK1-sdAb-TK1 complexes was
also performed with VDM software.

PCR amplification and cloning into pET-scFv-T
Sequences of the sdAb fragments were amplified from the phagemid plasmids
corresponding to the isolated positive clones in phage ELISA. The sequences were amplified
using primers containing the NcoI restriction site (5’ GAACATATGATGAAAAAATTATTA
3’) and the NotI restriction site (5’ GAAGGATCCTGCGGCCCCCTTTC 3’). PCR products
were run in a 1% agarose gel and desired sequences were extracted using the Zymoclean DNA
Gel Recovery Kit (Zymo research, Irvine, CA, USA). Following gel recovery, sdAb sequences
were digested using NcoI and NotI restriction enzymes (New England Biolabs, Ipswich, MA,
USA). Digested sequences were then ligated into the pET-scFv-T backbone (Addgene,
Watertown, MA). Ligation was carried out using the Quick Ligation kit (New England Biolabs,
MA). The ligated plasmids were then cloned into Dhα5 competent cells. Transformed colonies
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were grown for 16- 20 hours and plasmids were isolated and analyzed by restriction enzyme
analysis to verify the presence of the insert. Positive clones were then sequenced.

Expression of antibody fragments in Rosseta 2(DE3) pLysS E. coli cells and His-tag purification
The pET-TK1-sdAb-6xHis constructs were cloned into Rosseta blue (DE3) pLysS E. coli
cells (Millipore SIGMA, St Louis, MO). Individual colonies were selected and grown in a
culture overnight at 37°C. The overnight culture was then scaled up and grown until the OD600
reached 0.6. Expression of the sdAb fragments was induced by addition of 0.4 mM Isopropyl βd-1-thiogalactopyranoside (IPTG). After IPTG induction, the cultures were grown for 24 hours at
28°C. The Rosseta blue (DE3) pLysS E. coli cells were pelleted, and the supernatant was saved
for later purification. The cells were subjected to osmotic shock by resuspending cells in TES
buffer (20 mM Tris-HCl pH 7.6, 5 mM EDTA, and 20% sucrose). After one hour incubation on
ice, the sample was centrifuged at 14,000 x g for 20 minutes. The pellets were resuspended in
ddH O and incubated on ice for 30 minutes. Centrifugation was repeated and the supernatant was
2

preserved. The cell pellet was lysed using 10x bug buster reagent (Millipore SIGMA, St Louis,
MO) diluted in 20 mM Tris–HCl (pH 7.8) buffer containing 15 mM NaCl, 5 mM MgCl2, DNase
(25 U/ml) and protease inhibitors. Cells were lysed for 20 minutes on shaker with moderate
agitation. The lysed cells were spun down at 16,000 x g for 20 minutes and the supernantant was
recovered. Supernatants were mixed with equilibrated Ni-NTA agarose beads (Qiagen, Hilden,
Germany) for 3 hours at 4 ºC. After incubating the NI-NTA beads were washed twice with cell
lysis buffer and placed into 5 ml polypropylene columns. The Ni-NTA beads were then washed
with 50 ml of wash buffer and then the His-tagged proteins were eluted with elution buffer in 0.3
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ml fractions. The fractions were analyzed by SDS-PAGE and Western blot to detect the purified
anti-TK1 sdAb fragments and estimate their purity.

sdAb ELISA
TK1 sdAbs expressed in a pET system and purified were tested again in ELISA to
confirm that their binding properties to TK1 were kept when expressed without being fused to
the PIII coat protein of the phages. The ELISA was performed as previously described for phage
ELISA, except the blocking solution was replaced with 5% BSA. Because these antibodies were
expressed with a VSV-G-tag this time the detection antibody was an anti-His-HRP (Biolegend,
San Diego, CA) or anti-VSV-G-HRP (Bethyl, Montgomery, TX) rather than an anti-M13-HRP
antibody.

Western blot with purified anti TK1-sdAb fragments
The purified fragments were tested for their capacity to bind to purified TK1 and TK1 in
cell lysate using Western blotting. Recombinant human TK1 produced in bacteria and Expi293F
cells were used together with cell lysate from A549 lung cancer cells, including a siRNA TK1
knockdown cell lysate. Briefly, 0.5 μg of TK1 or 20 μg of cell lysate were mixed with 6x
Laemmli buffer (Millipore SIGMA, St Louis, MO). The protein samples were then heated at 100
ºC for 5 minutes and loaded into a 12 % SDS-PAGE electrophoresis. The proteins from the gel
were then transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). After
blocking with 5 % milk in MPBS buffer for 1 hour at room temperature the blocking solution
was poured off and anti-TK1 sdAb fragment solution (1 μg/ml-2 μg/ml) was added. Membranes
were incubated at 4 ºC overnight. After overnight incubation membranes were washed 3 times
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with PBS-T buffer. The bound proteins were detected using a 1:20,000 solution of an anti-VSVG-HRP and anti-His-HRP antibody (Bethyl, Montgomery, TX, USA). The proteins were then
detected through the peroxidase reaction using enhanced chemiluminescence (ECL) (Advansta
Corporation, San Jose, CA). Films were exposed for differing amounts of time depending on the
antibody being tested, times ranged from 30 seconds to 5 minutes. The films were scanned, and
the images were analyzed using the software ImageJ from NIH.

Cell lines and Isolation of human MNCs
The NCI-H460 (ATCCHTB-177 ), A549 (ATCC CCL-185), HCC1806 (ATCC CRLTM
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2335 ) and HT-29 (ATCC HTB-38 ) cell lines were obtained from the American Type Culture
TM

®

TM

Collection (ATCC, Manassas, VA, USA) and maintained according to ATCC recommendations.
A549, NCI-H460, HCC1806 and HT-29 were cultured in RPMI-1640 media (ThermoFisher
scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) and 2mM LGlutamine. All cell lines were grown in an incubator at 37 °C and 5% CO . All cell lines used
2

were tested for TK1 surface expression with flow cytometry with the commercial antibody
ab91651 (Abcam, Cambridge, UK) to confirm the presence of TK1 on the cell membrane.
MNCs were isolated using lymphocyte separation media (Corning, NY) following the
instructions from the product’s manual, red blood cells were depleted with red blood cell lysis
buffer (Biolegend, San Diego, CA) and the MNCs were resuspended in LGM-3 (Lonza, Basel,
Switzerland). Isolation of human MNCs and serum from blood was done under approval of the
Brigham Young University Institutional Review Board number 1734.
Flow cytometry
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The purified phage-sdAb fragments, anti-TK1 sdAb fragments, and anti-TK1-sdAb-IgG1
fusions were all tested for their capacity to detect mTK1 on the cancer cell lines NCI-H460,
HCC1806, HT-29, and normal MNCs. For this analysis 1x106 cells per sample were analyzed.
Cells were washed twice with PBS and resuspended in 200 μl of cell staining buffer. After
resuspension, the cells were stained using PEG purified phage-TK1-sdAb fragments (100 μl),
purified sdAb fragments (5-10 μg), or purified sdAb-IgG1 antibodies for 40 minutes. The cells
were then washed 3 times with 200 μl of cell staining buffer and stained for 30 minutes with
anti-his-APC or anti-VSV-G-FITC antibodies or, in the case of purified phage-sdAb fragments,
anti-M13-FITC secondary antibody. To detect binding of sdAb-IgG1 antibody fusions antiHuman IgG-FITC antibody (Abcam, Cambridge, UK) was used. After incubation with secondary
antibody, the cells were washed 3 times with 200 μl of cell staining buffer. Before analysis
samples were stained with 10 μg/ml PI solution and the samples were analyzed in a Cytoflex
flow cytometer machine (Beckman Coulter, Brea, CA). The FCS files were analyzed using the
FlowJo software (FlowJo, Inc., Ashland, OR).

Incorporation of TK1-sdAb fragments into pFUSE-IgG1 constructs and antibody expression in
CHO cells
The DNA sequences of the best two anti-TK1 sdAbs were cloned between the NcoI and
EcoRI restriction sites of the pFUSE-hIgG1e5-Fc2 vector (InvivoGen, San Diego, CA). This
vector is designed for the production of human recombinant antibodies in mammalian cells and
contains a human IgG1 heavy chain mutated at the S239D/A330L/I332E sites which confers an
increased binding to FcγIIIa receptors in macrophages (MO) and natural killer cells (NK). Thus,
the recombinant antibodies fused to this engineered IgG1, can elicit an enhanced antibody82

dependent cell-mediated cytotoxicity (ADCC). The primers used for the amplification of the
sdAb fragments for this construct were primer Fw- 5’
GAAGAATTCGATGGCCGAGGTGCAG 3’ and primer Rv- 5’ GGCCCATGG
CGCTCGAGACGGTGAC 3’. The two TK1-scFv-hIgG1 DNA constructs were introduced into
CHO.K1 cells (ATCC, Manassas, VA, USA) by lipofection using the lipofectamine LTX reagent
(ThermoFisher scientific, Waltham, MA). After 48 hours the media was changed and Zeocin
selection antibiotic (InvivoGen, San Diego, CA, USA) was added at a concentration of 100
μg/ml. After 10 days in selection the cells were expanded. The media was then replaced with
ProCHO AT (Lonza, Basilea, Switzerland) and the cells were incubated for 48-96 hours or until
TM

cell viability was about 50%. The media was collected and cleared from cells by centrifuging at
200 x g. The anti-TK1-scFv-hIgG1 antibodies where then purified from cleared media using
protein A purification columns (ThermoFisher scientific, Waltham, MA). Characterization of the
purified recombinant antibodies was carried out with Western blot and flow cytometry as
described above.

In vitro testing of anti-TK1-sdAb-IgG1 Antibodies through ADCC
The capacity of the TK1-sdAb-IgG1 antibodies to target mTK1 on cancer cells and elicit
an ADCC response was evaluated in vitro. For this experiment NCI-H460 cells, which expressed
high levels of mTK1, were engineered to express cytosolic GFP. The cells were then co-cultured
with human MNCs and anti TK1-sdAb-IgG1 antibodies were added in various concentrations.
Cell death was then measured using a real time cell imaging system. The experiments were
conducted as follows. One day before treating the cells with antibodies and controls 5000 NCIH460 GFP+ cells were seeded per well in a 96-well tissue culture plate (MIDSCI, St. Louis,
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MO), placed inside an ImageXpress Pico system. The GFP+ cells were counted every hour for
®

the next 8-12 hours. After initial growth human MNCs were added at two different ratios, 5:1
and 10:1. The cells were co-cultured using LGM-3 media to sustain MNCs and antibodies were
added at various concentrations (20, 10, 5, 2.5 μg per well). An optimized 5:1 effector:target
ratio and a concentration of 10 μg of antibody/ml were used for experiments. The cells were
monitored for 72-96 hours under environmentally controlled conditions. The number of cells
from each treatment including controls were analyzed and compared over time. Each treatment
in the assay was run in duplicate wells and the experiment was repeated twice.

Statistical analysis
Statistical analyses were performed using the GraphPad Prism software (GraphPad, San
Diego, CA). ELISA data from dilution curves was log-transformed and analyzed with a 4parameter non-linear regression analysis with a 95% confidence interval (CI). To compare the
different treatments of the ADCC experiments, the data was normalized in reference to the
moment MNCs and antibodies were added and analyzed using a two-way ANOVA with repeated
measure analysis. Analysis of multiple comparisons was performed comparing the mean of each
treatment with every other treatment mean in each time point and over the total course of time.
One-way ANOVA was performed to compare normalized GFP+ cell counts at specific time
points.
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Results
Antigen validation
All of the antigens used for the selection of the sdAbs were validated before the
biopanning process. Recombinant human TK1 was produced in E. coli (E-TK1) and was used
during early rounds of selection at high concentrations while TK1 produced in human Expi293F
cells (H-TK1) was used for the last two rounds of selection at lower concentrations. This is
because H-TK1 produced in human cells is properly folded. Both antigens were validated using
Western blot with the KO validated anti-TK1 antibody ab91651 (Abcam, Cambridge, UK). Both
E-TK1 and H-TK1 purified fractions were positive for TK1 and showed bands respective to the
monomer and dimer of TK1. The purity of the antigens was shown to be higher than 80% based
on the SDS page and Coomassie blue staining (Fig 3-1A, right).

Figure 3-1. Antigen validation and quantification of eluted phages thorough rounds of selection. A, Antigen
validation, the purity and integrity of human recombinant TK1s produced in E. coli cells and Expi293F cells were
assessed in SDS-PAGE and validated using Western blot with the anti-TK1 antibody ab91651. B, Enrichment of
TK1 binders through 5 rounds of selection. The number of binders was estimated based on titrations of eluted
phages used to infect TG1 bacteria. C, A representative image of a viral titration to determine the number of eluted
phages. TG1 bacteria were infected with serial dilutions of the eluted phages after each biopan. The infected TG1
bacteria were then plated on TYE amp plates.
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Isolation and validation of anti-TK1 sdAb fragments
The isolation of anti-TK1-sdAbs was monitored after each biopan by determining the
phage titer from the eluted phages. As expected, the number of eluted phages per ml increased
exponentially through the 5 rounds of selection (Table 3-1, Fig 3-1B). This trend could be
observed by infecting TG1 bacteria with the eluted phages, plating the bacteria in selective agar
plates and then determining the number of CFU/ml (Fig 1C). After 3 consecutive rounds of
selection with recombinant human TK1 produced in E. coli the enrichment factor of TK1 binders
went from 1 to 48.9. (Table 3-1). Two more rounds of selection were performed using
recombinant H-TK1 to eliminate non-specific sdAb fragments that could possibly bind to the
His-tag present in E-TK1 and also to obtain fragments that could bind to properly folded human
TK1. We observed that the enrichment factor increased 3-fold after 1 round of selection with HTK1 and then doubled in the subsequent round of selection using H-TK1.

Table 3-1. Enrichment of anti-TK1-sdAb phages through 5 rounds of selection.
Round of selection

Input phages

Eluted phages

Ration (eluted/input)

Enrichment factor

1

5.00E+12

4.12E+04

8.24E-09

1.00

2

5.00E+12

1.60E+06

3.20E-07

38.83

3

5.00E+12

2.01E+06

4.03E-07

48.91

4

5.00E+12

5.20E+06

1.04E-06

126.21

5

5.00E+12

1.13E+07

2.27E-06

275.49

An exponential increase in the number of positive clones after each biopan was observed.
About 50 % of the clones produced a positive signal by the 4th biopan and about 90% of the
clones were positive in the 5th biopan (Fig. 3-2A). A similar trend was observed in polyclonal
phage ELISA (Fig. 3-2B).
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Figure 3-2. Selection and expression of anti-TK1-sdAb phages. A, Analysis of 80 clones using monoclonal phage
ELISA was performed after each round of selection. B, Polyclonal phage ELISA using the total purified phages per
round of selection. In both A and B the overall signal and number of positive clones increased after each round of
selection. C, Detection of anti-TK1-sdAb phages using dot blot with an anti-VSV-G-HRP antibody. Also,
verification of packaging of the library from PEG purified phages after initial amplification of the sdAb library. D,
Representative image of monoclonal phage ELISAs during the rounds of selection.

In addition to monoclonal and polyclonal phage ELISAs, we screened purified phages
and individual supernatants containing phages with Western blot and dot blot. Since each
antibody fragment displayed in the M13 phages had Myc and VSV-G tags, we detected the
production of phage-antibodies using anti-VSV-G-HRP conjugated antibody. Western blot
analysis of the purified phages revealed the presence of bands corresponding to phage-sdAb
fusions. Dot blot analysis of individual clones showed the successful production of individual
phage-sdAbs (Fig 3-2C). After the initial screens using monoclonal phage ELISA, 26 clones
were chosen for their ability to produce high signals. These included clones from the 2 , 3 and
nd

rd

4 rounds of selection. Clones from the 5 biopan were excluded due to a decrease in the
th

th
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diversity of the sdAb sequences. The clones were re-tested to confirm their capacity to bind TK1
and reproduce a positive signal. From the 26 selected clones, 14 clones were able to reproduce a
positive signal after the initial screen (Fig 3-3).

Figure 3-3. Confirmation of positive clones. To verify the positive clones found during the initial screening, their
capacity to reproduce a positive signal was tested. The strongest positive clones were selected through the different
rounds of selection. Bacteria corresponding to each of these clones were streaked for a second time on TYE amp
plates. New cultures were grown from a single colony and infected with KM13 helper phage to induce the
production of their respective anti-TK1 phage-sdAbs. A, Positive anti-TK1 phage-sdAbs tested in monoclonal phage
ELISA. The capacity to bind TK1 and the stability of each clone was confirmed. B, Representative image showing
the color development generated by the positive clones and plate layout indicating the position of each clone that
was tested.

After confirming their binding to TK1, the positive clones were evaluated using dose
calibration curves to determine if they bound to TK1 quantitatively and to determine their
sensitivity. The 14 clones showed all sigmoidal curves according to our non-linear 4-point
logistic analysis. The goodness of fit test showed R squares ranging between 0.9964-0.9772. The
curves behaved according to receptor-ligand interactions models, showing that the binding of the
anti-TK1-sdAbs were proportional to the concentration of TK1 in each well (Fig 3-4A). This
could also be visually appreciated in the colorimetric reactions in the dilution curves for each
clone (Fig 3-4B). There was no significant background signal produced by the clones in the
blanks.
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Figure 3-4. Testing of the anti-TK1 sdAbs with dose response curves. A, Dose response curves corresponding to
anti-TK1 sdAb fragments obtained through various rounds of selection. The data was Log transformed and the
curves were analyzed using a 4-parameter non-linear regression. B, A representative image of the colorimetric
reaction showing that the signal of each anti-TK1 sdAb fragment is proportional to the concentration of TK1
protein. Negligible or no significant signals were produced in the blanks.

The most sensitive clones were 4-H-TK1_A1 and 4-H-TK1_D1. Using the phage
supernatant from these clones we were able to detect TK1 protein levels as low as 23 ng/ml in
monoclonal phage ELISA (Fig 3-5A). Further sequencing of the clones revealed that the
sequences of clones 4-H-TK1_A1 and 4-H-TK1_D1 were different.
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Figure 3-5. Sensitivity and specificity of the anti-TK1-sdAb fragments. A, The 14 anti-TK1 sdAb fragments were
tested against a minimal fixed concentration of 23 ng/ml of human TK1 produced in human cells (H-TK1). The
sdAbs 4-H-TK1_A1 and 4-H-TK1_D1 produced the highest signals. B, Dilution curves with H-TK1 and the best
clones. Concentrations ranged from 500 ng/ml to 3.9 ng/ml, the fragments kept their binding properties after being
expressed as sdAb fragments C, siRNA TK1 knock down validation. TK1 was knocked down in A549 cells. The
knockdown was validated using the commercial anti-TK1 antibody ab91651. D, Validation of the best 2 anti-TK1sdAbs. The binding capacity of the sdAb fragments was tested against 3 different sources of human recombinant
TK1, cell lysate from the cancer cell line A549 and cell lysate from A549 TK1 knockdown. It can be seen that both
fragments bind to all recombinant TK1 proteins. A significant difference can be seen in the signal coming from the
normal cell lysate in comparison with the TK1 knockdown cell lysate.

Anti-TK1-sdAbs phages 4-H-TK1_A1 and 4-H-TK1_D1 demonstrated the capacity to bind H-TK1 in
phage ELISA. The signal was proportional to H-TK1 concentration (Fig 3-5B). Validation of the clones
4-H-TK1_A1 and 4-H-TK1_D1 using a siRNA TK1 knockdown and different sources of recombinant
human TK1 revealed that the clones were able to bind to E-TK1(produced in E. coli), H-TK1(produced in
Expi293F cells) and TK1 produced in a yeast system. Moreover, the signal with cell lysate from A549
cells was significantly stronger (~10-fold) to the signal coming from the cell lysate of A549 TK1
knockdown for both 4-H-TK1_A1 (P<0.0296) and 4-H-TK1_D1 (P<0.0129). A TK1 knock down was
produced as previously described for this experiment (Fig 3-5C and D) 191.
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Flow cytometry

Membrane expression of TK1 on NCI-H460 cells was detected by staining the cells with
PEG purified phages from each respective clone. We observed that after subtracting the
background binding from the anti-M13-APC antibody there was an increase in binding to the
cells stained with the anti-TK1-sdAbs of 20% and 25% for H-4-TK1_A1 and H-4-TK1_D1
sdAbs respectively (Fig 3-10A). Therefore, the anti TK1 sdAbs showed a capacity to detect
membrane expression of TK1 on NCI-H460 cells. NCI-H460 cells were simultaneously screened
with the commercial anti-TK1 antibody ab91651.
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Figure 3-10. Detection of mTK1 on cancer cells and healthy MNCs using anti-TK1 sdAb fragments. A, NCI-H460
cells were stained with the purified phage-anti-TK1 sdAb fragments, a shift in the population could be observed
using both phage-sdAb fragments. B-E, Expressed and purified anti-TK1-sdAb_A1 and D His-tagged and VSV-G
tagged were used to stain NCI-H460 (lung), HT-29 (colon), HCC1806 (Triple negative breast cancer) and healthy
lymphocytes. The TK1 levels detected using the anti-TK1 sdAb fragments were comparable to the levels detected
by commercial anti-TK1 antibody. The highest levels of mTK1 were detected on NCI-H460, followed by HT-29
and then HCC1806. No significant binding was detected on normal MNCs with the anti-TK1 sdAb fragments nor
with the commercial anti-TK1 antibody. F, The expression levels of mTK1 on cancer cells and the binding of antiTK1 sdAb fragments. Only A1-His sdAb showed consistent binding similar to commercial antibody ab91651.
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After confirming the capacity of the TK1-sdAb-phages A1 and D1 to detect mTK1 on
cancer cells the fragments were expressed as sdAbs and used to stain different cancer cell lines to
confirm their ability to detect mTK1. The sdAbs were expressed as two different versions; Histagged and VSV-G tagged. Among the 4 sdAbs, TK1-D1-His showed the most consistent
binding to mTK1 on NCI-H460(~95%), HT-29(~87%) and HCC1806(~53%) (Figs 3-10B-10F).
These expression levels were comparable to those seen with the commercial TK1 antibody
ab91651; 97%, 72% and 55% for NCI-H460, HT-29 and HCC1806 respectively. For NCIH460,
which had the highest percentage of cells positive for mTK1, the A1 His-tagged sdAb fragment
and both the A1 and D1 VSV-G tagged sdAbs showed binding (Fig 3-10B). D1-VSV-G
fragment showed no binding to HT-29 cells or HCC1806 while A1-VSV-G and A1-His showed
variable levels of binding to both cell lines. However, not consistently as the D1-His fragment.
This may be due to differences in their tags, expression levels in each cell line and possible
binding to different epitopes. No significant binding of the anti-TK1 sdAb fragments and the
commercial anti-TK1 antibody was found on normal lymphocytes after subtracting non-specific
binding of secondary antibody anti-Human IgG FITC (Fig 3-10E). It can be appreciated that the
cancer cell lines expressed variable levels of mTK1 NCI-H460 being the one with the highest
percentage of positive cells followed by HT-29 and HCC1806 (Fig 3-10F).

Amplification of sdAB fragments, sequencing and cloning into pET-scFv-T vector

The dAb fragments were amplified by PCR and ligated into the pEt-scFv-T vector
successfully as shown in figure 3-6. The anti-TK1-sdAb vectors were sequenced, and the amino
acid sequences were deduced from their nucleotide sequences (Table 3-2).
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Figure 3-6. Amplification and ligation of anti-TK1-dAb fragments into the pET-scFv-T expression vector. A, a
representative image of a PCR showing amplification of anti-TK1 dAb fragments. B, Restriction enzyme analysis
with NcoI and NotI enzymes of pET-anti-TK1-dAb constructs. C, Map of a pET-anti-TK1-dAb construct.
Fragments are ligated into the pET-scFv plasmid using NcoI and NotI restriction sites. D) Alignment of the 4-HTK1_A1 and 4-H-TK1_D1 sdAb sequences shows that the differences of the sdAbs are in their CDRs.

Further analysis of the nucleotide sequences of the Anit-TK1 dAb fragments with the IgG
blast tool from NCBI revealed the specific sites for their respective CDRs. The annotated
sequences are found in Table 3-2. In addition, the alignment of the sequences using Genious
software confirmed that the annotated CDRs were the regions with most differences among the
sequences while the heavy chain framework regions remained conserved (See Fig. 3-6D). This is
consistent with the original description of the library which was built in a human VH framework
and introduced diversity in the CDRs.
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Table 3-2. The deduced amino acid sequences of the best two anti-TK1 sdAb fragments isolated
through phage display.
Anti-TK1 dAb

FR1

CDR1

FR2

CDR2

4-H-TK1_A1

MAQVQLLESGGGLVQPGGSLRLSCAA

SGDRFTDEN

MSWVRQAPGKGLEWVSA

IDNADGST

4-HTK1_D1

MAQVQLLESGGGLVEPGGSLRLSCAAS

GDSFTTKN

MAWVRQAPGKGLEWVSA

ISKRSGST

Anti-TK1 dAb

FR3

CDR3

FR4

4-H-TK1_A1

YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

AAGFVHAVVQKEFYYSPVKF

WGQGTLVTVSSAAAG

4-HTK1_D1

YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

AGLTQRHGHAKLKY

WGQGTLVTVSSAAAG

Analysis of protein structure of Anti-TK1-sdAb fragments and modeling of sdAb-TK1
complexes
After submitting the corresponding amino acid sequences from the anti-TK1 sdAb
fragments A1, and D1 into the GalaxyTBM server, 5 model structures were generated for each
fragment. The most stable structure from each anti-TK1-sdAb was then visualized using the
VMD software. The anti-TK1-sdAb fragments presented a typical structure of a sandwich of two
antiparallel β sheets according to previously reported single domain structures 204. Their CDRs
were contained in the loops connecting their antiparallel β sheets with CDR3 displaying a longer
loop as expected and in accordance with the sdAb library design (Figs 3-7A and 3-7B).
Furthermore, analysis of the interaction between the anti-TK1_4-H-A1 sdAb and the 1XBT
crystal structure of TK1 using the high ambiguity driven protein-protein docking (HADDOCK)
web server revealed the interaction of the anti-TK1 sdAb 4-H-TK1_A1 through its CDRs with
TK1 205. The CDRs seemed to interact with the α1-ribbon towards the N-terminus and two
regions close to the β-ribbons at the c-terminus of the TK1 molecule (Fig 3-7C and 3-7D).
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Figure 3-7. The 3D structure of the two best anti-TK1-sdAb fragments based on their deduced amino acid
sequences. The anti-TK1-sdAb fragments were modeled using the GalaxyWeb TBM server. The most stable
structures were then visualized using the VMD 1.9.3 software. CDRs were mapped by analyzing the anti-TK1 sdAb
amino acid sequences with the IgBlast tool from NCBI. A, H-4-TK1_A1 sdAb. B, H-4-TK1_D1 sdAb. C, High
ambiguity driven protein-protein docking analysis using the HADDOCK 2.4 web server. The most stable structures
of the H-4-TK1-A1 sdAb fragment and human TK1 protein monomer were analyzed to predict their protein-protein
interactions. The analysis shows that in the most stable TK1-TK1sdAb complex, the TK1-sdAb would bind to TK1
through its CDRs. The CDRs would interact with the α1-ribbon towards the N-terminus and two regions close to
the β-ribbons towards the c-terminus of the TK1 molecule. D, Docking between the anti-TK1 sdAb H-4-TK1_A1
and the monomer of human TK1 from the 1XBT crystal structure.

Expression and characterization of purified sdAb fragments

The anti-TK1 sdAbs H-4-TK1_A1 and H-4-TK1_D1 were successfully expressed using
the pET-scFv-T system. The fragments were detected with anti-His-HRP and anti-VSV-G-HRP
antibodies in Western blot as could be observed (Fig. 3-8A). Moreover, coomassie blue staining
showed successful purification of a 12-15 kDa band which matched the size of the band shown
in Western blot. Purification of sdAb fragments with Ni-NTA bind-His resin yields were
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between 1 up to 4 mg/ml of purified fragment (Fig. 3-8B). Alternatively, the fragments that are
VSV-G-tagged were purified using protein A columns (Fig. 3-8C). Although, the yields in
protein A purification were lower, about 0.4 mg/ml (Fig. 3-8D).

Figure 3-8. Expression and purification of anti-TK1 sdAbs. A, Detection of anti-TK1 sdAb fragments with anti-HisHRP antibody in Western blot and their respective SDS-PAGE analysis. B, Quantification of the His-tag purified
sdAb fragments with BCA assay. The protein yields ranged between 1-4 mg/ml of purified sdAb. C, Western blot
and SDS-PAGE analysis of protein A purified anti-TK1 sdAb H-4-TK1_A1. The antibody fragments can
alternatively be purified with protein A purification. D, Quantification of protein A purified anti-TK1 sdAb H-4TK1_A1.

Western blot and sdAb ELISA

After being expressed as sdAb fragments without a PIII gene fusion, the purified antiTK1-sdAbs retained binding properties to TK1 similar to those observed when expressed as PIII
fusions displayed on filamentous KM13 phage. Thus, indicating that their binding is due to the
sdAb sequence and not through non-specific interaction of the coat proteins of the KM13 phage.
This was tested using sdAb ELISA. As shown, the anti-TK1 sdAbs bound proportionally to the
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concentration of TK1 in the wells. Concentrations ranged between 500 ng/ml-3.9 ng/ml of HTK1. The anti-TK1-sdAbs produced signals significantly higher than the blanks at
concentrations of 3.9 ng/ml for H-4-TK1-A1 and for H-4-TK1-D1, with both signals reaching
plateau phase after 125 ng/ml (Fig 3-9A).

Figure 3-9. sdAb ELISA and Western blot analyses. A, Purified recombinant anti-TK1 sdAbs kept their binding
properties to H-TK1 after being expressed in E. coli and His-tag purified as observed using sdAb ELISA. B, The
anti-TK1 sdAbs showed binding to recombinant human TK1 produced in both E. coli (E-TK1) and human cells (HTK1). The fragments were validated by comparing their binding to TK1 in cell lysates of A549 cells (100 μg) and
A549 TK1 knockdown (100 μg). C, Detection of TK1 in cell lysates of 4 different cancer cell lines and normal
MNCs (20 μg each). The fragments were able to detect the tetrameric form of TK1, controls included commercial
anti-TK1 abcam91651 and GAPDH.

The anti-TK1-sdAbs were then tested in Western blot. As can be observed in Fig. 3-9B,
the anti-TK1-ssdAbs showed binding to recombinant human TK1 produced in E. coli, and
Expi293F cells. Moreover, the Anti-TK1 sdAb fragments showed a significantly higher signal in
A549 cell lysate compared to A549 TK1 siRNA knockdown, particularly fragment 4-H-TK1_A1
showed specificity for TK1 (Fig. 3-9B).
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Once we confirmed the binding of the fragments to purified recombinant TK1 and
validated their specificity using a TK1 siRNA knockdown we proceeded to test their capacity to
detect TK1 in cell lysates of different cancer cell lines, including, NCI-H460, HT-29, MDA-MB231, PC3 and human MNC. It could be observed that the anti-TK1 sdAb OriTK1_A1-VH was
able to detect bands corresponding 100 kDa in several cell lysates except in MDA-MB-231 cells
where it seems to detect a 50 kDa band instead. Also, the signals for cell lysates from HT-29 and
H460 were weaker than the signals coming from other cell lysates. In the case of the anti-TK1
sdAb OriTK1_D1-VH we obtained stronger signals in all cell lysates compared to the signal of
OriTK1_A1-VH. OriTK1_D1-VH also detected a 50 kDa band in MDA-MB-231 cells in
addition to the 100 kDa band (Fig 3-9C). These may correspond to the active dimer and tetramer
forms of TK1.

Cloning of the Anti-TK1-sdAb fragments into the pFUSE-IgG1e5 vector and expression of
recombinant antibody in CHO.K1 cells.

Before cloning the anti-TK1-sdAb sequences into an expression vector, site directed
mutagenesis (SDM) was performed to change the amber stop codons present in the sdAb
sequences to glutamic-acid. The anti-TK1-sdAb fragments were then successfully ligated into
the pFUSE-IgGe5-IL2 expression vector at the NcoI and EcoRI restriction sites. Restriction
analysis of these constructs showed the successful insertion of the sdAb genes into the pFUSEIgGe5-IL2 vector (Fig 3-11A). After 72 and 96 hours of transfecting CHO.K1 cells with the
pFUSE-4-H-TK1_A1 and D1, and a control without sdAb construct, the collected supernatants
were purified using a protein A column. The recombinant antibodies were successfully purified
from supernatant with a yield of 0.4-0.26 mg/ml. Western blot analysis and SDS page showed
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for both sdAb-Fc antibodies a ~38-40 kDa band which is the expected size for the monomer of
the anti-TK1-sdAb-IgG1 fusion. In the case of the control vector containing an IgG1 sequence
without being fused to a sdAb sequence an IgG1 fragment of smaller size (~26 kDa) was
produced. The recombinant antibodies were all positive in Western blot to anti-human IgG
antibody confirming the presence of the engineered IgG1 heavy chain fused to the sdAbs (Fig 311B). Furthermore, the anti-TK1-sdAbs once fused to IgG1 Fc were able to detect recombinant
purified human TK1 (H-TK1). The signal produced in Western blot was proportional to the
concentration of antigen and was higher than the signal produced with anti-TK1 sdAbs without
FC fusion (Fig 3-11C). In addition, the recombinant antibodies showed capacity to detect mTK1
on cancer cells in flow cytometry (Fig 3-11D). A shift in the population of NCI-H460 cells could
be seen when they were stained with the TK1-A1-IgG1 and D1 antibodies while no shift was
detected using IgG1 fragments without fusion to TK1-sdAbs.

Figure 3-11. Expression and testing of the Anti-TK1 sDab-IgG1 antibodies. A, Construction of an anti-TK1 sdAb
fragment. Restriction analysis of pFUSE-anti-TK1-sdAb plasmids and their respective maps. B, Expression and
detection of anti-TK1-sdAb-IgG1 antibodies. As can be observed sdAb-IgG1 fusions produced higher molecular
weight bands compared to IgG1-no sdAb constructs. No human IgG was detected in non-transfected CHO.K1 cells.
C, After fusing to an Fc the anti-TK1-sdAb antibodies were able to detect mTK1 on NCI-H460 cells. IgG1-no sdAb
control did not bind to NCI-H460 cells.

Anti-TK1-sdAb antibodies elicited in vitro ADCC responses of human MNC against cancer cells
expressing mTK1
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To test the potential use of the anti-TK1-sdAb antibodies for the immunotargeting of
cancer cells that express mTK1, we co-cultured tumor cells expressing high levels of TK1 with
human MNCs, added anti-TK1-sdAb-Fc antibodies and monitored the ADCC response over
time. The NCI-H460 cell line was chosen as this cell was previously shown to express the
highest levels of mTK1 on the cell surface in flow cytometry (Fig 13-1F). An initial test using
different concentrations of anti-TK1-sdAbs showed that the cell killing was proportional to the
concentration of antibody used (Fig 3-12A) and it was found that a concentration of 10 μg/ml of
the engineered anti-TK1 antibodies was necessary to cause a significant ADCC response. Cells
treated with the anti-TK1-sdAb-IgG1_A1 and D1 antibodies at 10 μg/ml and co-cultured with
human MNCs had a significant ADCC response against the cancer cells when compared to
isotype (P<0.0395) and no antibody controls (P<0.0038) after 88 hours (Fig 3-12B). Although
the 2-way ANOVA analysis did not show the difference to be significant in the case of the antiTK1-sdAb-IgG1_D1 antibody, a reduction of more than 50% of target cells was observed
compared to isotype controls. Imaging of the cells revealed that after 96 hours there was a
difference in the cell health and number of MNCs clustering targets cells. It could be seen that
cells treated with anti-TK1-sdAb-IgG1 experienced a more severe ADCC response than those
treated with the isotype control (Fig 3-12B). Statistical analyses at individual time points
indicates that the percentage of cell killing is significantly higher at 96 hours when TK1 is
targeted using the anti-TK1-sdAb-IgG1_A1 (P<0.0267) and D1 (P<0.0265) compared to
controls and at 72 hours (P<0.0207 and P<0.0246 respectively) (Fig 3-12C).
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Figure 3-12. Anti TK1-sdAb-Fc antibodies elicit ADCC responses against NCI-H460 cells expressing mTK1. A,
Optimization of several antibody concentrations. The decrease in GFP+ NCI-H460 cells co-cultured with MNC over
time is proportional to the concentration of anti-TK1-sdAb-IgG1/ml used. B, A significant ADCC response is
elicited by MNCs against NCI-H460 cells when anti-TK1-sdAb-IgG1 antibodies are added compared to controls. C,
After 96 hours the cell killing can visually be appreciated to be more severe in the cells treated with the anti-TK1sdAb-IgG1 antibodies. D, Percentage of cell killing calculated every 24 hours. The percentage of cell killing was
significantly higher after 72 and 96 hr. when anti-TK1-sdAbs were added in comparison to IgG1 isotype control and
effector only-no sdAb control.
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Discussion

From its early beginnings, studies involving TK1 have been focused mainly on its use as
a tumor biomarker 205-207. However, new evidence has shown that TK1 may have an emerging
role as a target for cancer therapy. Recent studies on the suppression of TK1 in cancer cells have
shown that the silencing of TK1 decreases the capacity of lung adenocarcinoma, pancreatic and
thyroid carcinoma cells to proliferate, migrate or make mesenchymal transitions 34,151,189.
Additionally, some TK1 forms seem to be able to associate to the cell membrane of cancer cells,
an event that is apparently restricted to malignancy. Thus, it is clear that the development of
therapeutics that can specifically target TK1 are necessary to explore the potential of TK1 as a
target. Monoclonal antibodies are the fastest growing biopharmaceuticals in immuno-oncology
208

. Previously it has been shown that anti-TK1 monoclonal antibodies could be used for the

immunotargeting of TK1 on several cancer types 191. Although some monoclonal antibodies
against TK1 have been developed there are currently no humanized versions of TK1 antibodies
suitable for therapy 191,209. Moreover, the recent increase in the use of phage display antibody
libraries has proven the advantages of using sdAb fragments in the development of therapeutic
antibodies for cancer treatment. Single domain antibodies are characterized for their smaller size
while keeping all the binding properties of full-length antibodies 210. In this study anti-TK1
sdAbs were isolated from a sdAb library through phage display. This is the first time that the
isolation and characterization of 100% human sdAb fragments specific for TK1 has been
reported. This study also provides evidence that single domain antibodies or nanobodies can be
used to target mTK1 on cancer cells, an antibody approach that has not been previously used for
the targeting of TK1. Furthermore, this study shows evidence that TK1 sdAbs can be
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incorporated in engineered IgG1 antibody constructs to generate molecules for potential
immuno-oncology applications.

It is important to mention that the process through which we selected the antibodies using
TK1 produced in bacteria and TK1 produced in human cells was chosen to ensure that we
obtained a sufficient number of sdAbs and that the anti-TK1 sdAbs were able to bind to properly
folded human TK1. ELISA data in this study has shown that the anti-TK1 sdAbs fit the receptorligand model and that the binding of the anti-TK1-sdAb fragments was dependent on the amount
of available antigen. This study also showed that the anti-TK1-sdAbs were able to be expressed
without the PIII fusion while keeping their binding properties previously shown in phage
monoclonal ELISA. Validation with an siRNA TK1 knockdown indicated that the antibody
fragments developed were specific for human TK1. Furthermore, the flow cytometry data
showed that the nanobodies can potentially be used to target cancer cells expressing TK1,
particularly mTK1. This early evidence indicates that anti-TK1-sdAbs could be used for the
development of experimental TK1-based therapeutics such as anti-TK1-sdAb fragments that
could be conjugated with toxins or gold nanoparticles for anticancer photothermal therapy 211,212.
Moreover, these anti-TK1-sdAb fragments could also be used for the development of immunooncology therapeutics such as engineered antibodies or chimeric antigen receptors213.

As this study has shown, anti-TK1-sdAb-IgG1 antibodies are capable of targeting mTK1
on cancer cells and elicit an ADCC response by human MNCs against TK1 high-level expressing
cancer cells building on previous findings. Unlike previous anti-TK1 antibodies generated
through conventional hybridoma technology, these engineered antibodies are completely human,
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are significantly smaller than full length antibodies and have an engineered IgG1 to enhance the
ADCC response. Thus, they can have better tumor penetration than conventional antibodies, and
can be used to better engage the immune system with tumor cells. Although it remains unclear
why TK1 is localized to the cell surface of multiple cancer cell lines, the flow cytometry data and
ADCC results described here suggest that it could be feasible to harness the immune system
against tumor cells expressing mTK1. It is not the first time that a protein thought to be limited
to the interior of the cell has been reported to be on the cell surface. Examples can be found in
the HSP70 family of proteins. Although HSP70 proteins were thought to be limited to function
only inside cells, it is well documented that they are secreted and localized on the cell membrane
of cancer cells 214,215. Recent studies have shown that TK1 is present in exosomes 190. As with
HSP70 proteins a possible explanation could be that it is transitorily localized on the cell
membrane as exosomes exit the cell fusing to the cell membrane, and through non-conventional
protein-protein interactions. Moreover, it is also important to point out that other nucleotide
salvage pathway enzymes have been reported to be localized on the cell membrane e.g.,
hypoxanthine-phosphoribosyl transferase (HPRT). Targeting of this enzyme with monoclonal
antibodies has also been recently reported 216.

Conclusion

This study reports the isolation and evaluation of human single domain antibodies against
TK1 and their binding to the tumor proliferation biomarker TK1 on lung, colon and breast cancer
cells. The antibody fragments have potential as diagnostic and therapeutic agents, although
additional in vivo studies are required to confirm their efficacy. The antibody fragments can be
successfully incorporated into IgG1 Fc constructs for the production of completely human
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engineered antibodies able to elicit significant ADCC responses from human MNCs against
cancer cells expressing mTK1. The antibody fragments could potentially be used in other
therapies such as chimeric antigen receptors (CAR) for T cells or other recombinant antibody
constructs. The use of TK1 as a therapeutic target will enable the testing of experimental TK1based therapies.
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Abstract

Follicular lymphoma (FL) is the most common indolent Non-Hodgkin’s lymphoma
diagnosed in both the US and Western Europe and comprises about 70% of all cases. Although
the combination of different chemotherapy regimens with rituximab have had a significant
impact on progression free survival rates, FL remains a treatable but incurable disease where
patients frequently experience relapse and refractory events. Survival of patients decreases as
they age, and disease evolves towards aggressive diffuse large B cell lymphoma. Extensive
efforts have been made to timely diagnose and stratify the risk of FLs using biopsy, CT and PET
scans, ultrasound, MIR and traditional histology. In addition, the use of several prognostic
indexes such as FLIPI, FLIPI-2, and tumor burden measurements has helped physicians and
scientists in the management of FL patients. Because of its indolent nature and the lack of
clinically proven biomarkers, more than 50% of FL cases are detected in advanced stages.
Moreover, a subset of FL patients (~20%) experience poor survival rates (2 years). With the
recent development of new tyrosine inhibitors, epigenetic drugs, immunomodulators, immmuno
checkpoint antibodies and Chimeric Antigen Receptor (CAR) T cell therapies, there is an
increased necessity to predict FL patients' response. Gene expression profiles, mutational
landscape of relevant genes, serum cytokines, immune cell subsets, exosomes, microRNAs,
circulating tumor DNA and nucleotide salvage pathway enzymes are among potential predictive
FL biomarkers. In this review, we examine their predictive capabilities for early detection, risk
stratification, selection of therapeutic regimen, prediction of patient response and monitoring of
FL disease.
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Introduction

In the US and western Europe, Follicular lymphoma (FL) encompasses 20-40% of all
non-Hodgkin’s lymphomas (NHL) and 70% of all indolent lymphomas worldwide217,218. FL
originates in mature B cells at the bone marrow with the initial t(14;18)(q32;q21) translocation
resulting in placing the BCL2 gene under the control of the immunoglobulin heavy-chain
enhancer during defective VDJ recombination219. It is believed that B cells with this genetic
lesion (70-95% of all FL cases) then migrate from the bone marrow to lymph nodes where they
undergo malignant transformation during aberrant somatic hypermutation (aSHM) and class
switch recombination (CR) at germinal centers (GC) in the follicles220. Eventually, enough
genetic lesions accumulate and FL evolves to an aggressive form of lymphoma called diffuse
large B cell lymphoma (DLBCL) or undergoes histological transformation (HT), causing bone
marrow failure, susceptibility to infections, secondary cancers and death221,222.

Although FL has a high 5-year survival rate, because of its indolent nature 68 % of the
cases are diagnosed in stages II, III and IV when the cancer has spread to multiple
regions223. The majority of FL cases are diagnosed after age 50 after which the survival rate
decreases. When transformation of FL to diffuse large B cell lymphoma (DLBCL) takes place,
most treatments of FL do not generate patient response. Moreover, about 20 % of FL patients
have a poor prognosis and an overall survival rate (OS) of 2 years or less 224. Even though FL
can become a manageable chronic condition, patients frequently experience relapse and
refractory events which many times have a detrimental effect on the patients’ life quality225.
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Traditional diagnosis of FL lymphoma involves biopsy from surgery or bone marrow
aspirate, staining of cell surface markers and BCL2 cytosolic expression followed by imaging
using ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) and positron
emission tomography (PET)226. Although prognostic indexes and histologic analysis along with
imaging have been helpful in the management of FL patients, currently there is not a consensus
on how to treat FL patients. Also, prognostic indexes have shown a limited capacity to predict
patient response to therapy, detect FL at early stages or identify FL patients that are prone to
relapse or DLBCL transformation227. In addition, as new treatments for FL are available such as
Bruton’s tyrosine inhibitors, epigenetic drugs, phosphoinositide 3-kinase (PI3K) and BCL2
inhibitors, immunomodulators, immune checkpoint antibodies and cell adoptive therapies more
predictive biomarkers for FL are needed228. Among new potential predictive FL biomarkers are,
gene expression profiles, mutational landscape of relevant genes, serum cytokines, immune cell
subsets, exosomes, microRNAs, circulating tumor DNA and nucleotide salvage pathway
enzymes (Fig. 4-1). In this review we discuss the current status of predictive biomarkers for the
detection and monitoring of FL.
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Figure 4-1. Biomarkers through the course of follicular lymphoma (FL). Follicular lymphoma genetic lesions
originate in B cells at the bone marrow. Defective V(D)J recombination causes t(14;18)(q32;21) translocation
placing BCL2 gene under the IgGH gene enhancer rescuing B cells from apoptosis. B cells carrying the
t(14;18)(q32;21) translocation enter the lymph nodes either into the borders of the T- cells zone or into the
follicles. In the follicles t(14;18)+ B cells further differentiate by interacting with follicular helper T cells (TFH)
and follicular dendritic cells (FDC). The t(14;18)+ B cells then undergo intensive proliferation forming a
germinal center. The same B cells go multiple rounds of somatic hyper mutation (SMH) and class switch
recombination (CSR). This causes the accumulation of genetic lesion that eventually leads to evolution of the
disease to histological transformation or diffuse large B cell lymphoma (DLBCL). Besides t(14;18)(q32;21)
translocation other early genetic lesions are found in chromatin modifying genes. Other subsequent mutations
are found in genes P16/INK4, MEF2, BCL6, MYC, KLF4, MYD88, TP53, some of them have been associated
to later stages of FL and transformation to DLBCL. Infiltration of high number of cytotoxic T cells are related to
good prognosis. High numbers of CD163+ and CD68+ macrophages are related to both poor and good prognosis.
Expression of SIRP-α in high levels in CD14 monocytes and macrophages is correlated to unfavorable outcome
while low expression of SRIP-α is related favorable outcome. The presence of FOXP3+ Treg cells has been
reported with good prognosis. CD8+ T cells expressing high levels of PD-L1 have been correlated with
significant lower response to immunocheckpoint therapy. IL1R and IL2R, IL12, IL15 and other cytokines have
shown predictive value in FL. Mutations specific to FL can be detected by analyzing ctDNA. Exosomes and
miRNA can also be found in serum and utilized as prognostic biomarkers. Pyrimidine salvage pathway enzymes
such as TK1 and HPRT whose serum and expression levels are upregulated at early stages of FL and correlate
with cancer stage and aggressiveness.
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FLIPI, FLIPI-2, TMTV and other prognostic indexes

The FL international prognostic index (FLIPI) was created using data from 4,167 patients
in an international cooperation of 5 research groups between both the US and Europe. FLIPI uses
5 parameters: Age >60 years, hemoglobin <12g/dl, serum LDH> normal, Ann Arbor stage III/IV
and number of involved nodal areas >4. Three risk groups defined as low (presence of 0-1
adverse factors), intermediate (2 factors), and poor risk (> 3 factors)229. The FLIPI has been
validated in clinical trials with chemotherapy and chemoimmunotherapy using both OS and
progress-free survival (PFS)230. After the inclusion of rituximab for the treatment of FL, the same
group that created FLIPI proposed a new index that could better reflect the course of FL disease
in the era of immunochemotherapy. FLIPI-2 considers five parameters: 1) 𝛽𝛽2-microglobulin

(β2M) higher than the upper limit of normal; 2) longest diameter of the largest involved lymph
node longer than 6 cm; 3) bone marrow involvement; 4) hemoglobin level <120 g/l and 5) age
>60 years231. FLIPI-2 has been validated clinically showing correlation with FLIPI with some
studies suggesting that FLIPI-2 is somewhat superior to FLIPI. Although FLIPI and FLIPI-2
have been used with some success to classify patients into risk groups there has been difficulty in
using them to choose treatment or predict patient response to therapy. Moreover, these
prognostic indexes (PI) lack molecular elements and are not able to accurately predict relapse
events or DLBCL transformation232. F-fluorodeoxyglucose (FDG)-PET has been used to detect
active disease and determine total metabolic tumor volume (TMTV). TMVT in combination with
FLIPI-2 has shown to help in identifying patients with severe prognosis233. Another PI, the
PRIMA-PI is derived from FLIPI-2 and uses only β2M and bone marrow involvement. The PI
has 3 risk categories, high with a β2M 3mg/L with bone high with β2M level >3mg/ml and bone
marrow involvement; intermediate with β2M < 3mg/L with bone marrow involvement; and low
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with β2M < 3mg/L without bone marrow involvement. Although simpler and promising, its
prognostic capacity seems limited and further validation is required before its clinical
implementation234.

CD163+ and CD68+ macrophages, CD4+ and CD8+ T cells, and other immune cell subsets

Since FL originates in multiple lymphoid organs (bone marrow, lymph nodes, spleen, and
MALT), FL B cells are often surrounded by other non-malignant immune cells including
different subsets of T cells, B cells, macrophages, and follicular dendritic cells (FDCs). The
amounts of infiltrating immune cells and their activation states/phenotypes have a profound
effect in the course of FL. The amount of CD68+ and CD163+ tumor associated macrophages
(TAMs) have shown to be useful to predict OS and PFS. Multiple studies have shown that FL
patients with a higher number of CD68+ and CD163+ TAMs receiving chemotherapy had poor
prognosis whereas patients receiving immunochemotherapy had longer survival rates235,236.
Thus, the prognostic value of CD68+ and CD163+ TAMs may be dependent on therapeutic
regimens. Another biomarker useful to identify monocyte and macrophage subsets with
prognostic value in FL is SIRP𝛼𝛼. Using CD14 and the expression levels of SIRP𝛼𝛼 three subsets
of macrophages can be identified in FL (CD14+SIRPα , CD14−SIRPα , and CD14−SIRPα ).
hi

low

neg

Increased numbers of CD14−SIRPα low cells seem to correlate with better OS237. Infiltration of
cytotoxic T cells positive for granzyme B are an indication of an outgoing immune response at
the tumor site.. CD4+ and CD8+ cells positive for PD-L1 expression were found in higher
amounts in FL patients that responded well to immune checkpoint therapy238. Another T cell
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subset that has prognostic value are FOXP3+ regulatory T cells, whose presence is positively
correlated with OS239.
m7-FLIPI, mutational status of relevant genes, and gene expression profiling

Using deep DNA sequencing Pastorea et al. analyzed the mutation status of the coding
sequence of 74 recurrently mutated genes in lymphoma from two independent patient cohorts.
Clinical factors were used to establish a clinicogenetic risk model based on failure-free surviving
that included the mutation status of seven genes (EZH2, ARID1A, MEF2B, EP3000, FOXO-1
CREBBP, and CARD11), FLIPI and Eastern Cooperative Oncology Group (ECOG) performance
status19. Even though m7-FLIPI is the first known clinicogenetic model, there is some
controversy if it accurately can be used for risk stratification or implemented in the clinical
setting on a routine basis. It seems that m7-FLIPI is dependent on therapeutic regimen and may
need additional evaluation and adjustments240.

Besides the genes considered in m7-FLIPI, there have been other genes whose expression
signatures and mutational status have shown clinical relevance as biomarkers for FL.
Rearrangements and mutations in genes regulating proliferation such as the MYC have been
reported in indolent lymphomas and associated with poor prognosis in patients with advanced
stages of FL241. Mutations in genes involved in cell cycle regulation and programmed cell death
have been also reported in FL including CDNK2A, CDKN2B, TP53 and BCL2. Among early
lesions of FL that are reported are deletions of 1p36, gains of 7p and 12q chromosomes in related
onco and tumor suppressors genes including TNFRSF14, EZH2 and MLL2 genes242. Other
genetic lesions can occur later in the course of FL during aSMH in the proto-oncogenes BCL6,
RHOH/TFF, PIM1, PAX5, IRF4, ST6GAL1, BCL7A, CIITA, LRMP and SOCS1. Some of these
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mutations are frequently associated with malignant transformation of FL to DLBCL220. Other
relevant mutations with prognostic relevance in FL are mutations in MYD88, CXCR4, BCL6,
STAT6, TNFAIP3, IRF8 and ETS1 genes243.

The use of gene expression profiles for the management of FL patients has been assessed
using microarray and RNAseq data from patients of the Primary Rituximab and Maintenance
(PRIMA) trial. In a study conducted by Bolen et al. the impact of mutational load and of a 6gene (GZMA, GZMB, PRF1, IFNg, EOMES, and CD8A) effector T cell (T ) signature was
eff

utilized to classify patients into 2 groups, “inflamed” (Teff -high) and an “uninflamed” (Teff low), finding that patients in the inflamed group had longer PFS244. Huet et al. using data from
the same PRIMA trial identified 23 genes whose expression levels were associated with PFS and
reflected B cell biology and tumor microenvironment. The data obtained from the patients was
used to build a model that was able to identify the population of patients that were at high risk245.

Immunohistological and cell surface markers

Immunohistochemical staining and analysis of FL cells by flow cytometry is, for almost
all of the cases, positive for cell surface staining of CD19, CD20, CD22, CD79a, CD10 and
monoclonal immunoglobulin. Additionally, about 85%-90% of FLs overexpress cytoplasmic
BCL2 although it can vary depending on the grade of the disease. FL cells usually are negative
for CD5, CD11c CD23 and CD43. Loss of CD10 expression is usually an indication of
transformation of FL to DLBCL226,246. With the FDA approval of immunocheckpoint therapies,
the importance of PD-1 and PD-L1 expression on both immune cells and tumor cells has
acquired increased relevance in diagnosis and prognosis of B cell lymphomas. However, among
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B cell lymphomas FL expresses the lower levels of plasma PD-L1 and the expression of PD-L1
in tissue and peripheral blood may have independent prognostic value247.

Epigenetic changes

Mutation on chromatin modifying enzymes and dysregulation in methylation patterns of
tumor suppressor, cell cycle regulators and DNA repair genes have been reported as epigenetic
hallmarks of FL248. Misregulation of histone lysine methylation has been reported to be involved
in cancer and developmental defects. Particularly, methylations in H3K4, H3K36 and H3K79 are
related to active transcription, while methylations in H3K9, H3K27 and H4K20 are associated
with silenced chromatin states249. EZH2 is a H3K27 methyltransferase that when mutated is
related to favorable outcome and low risk. It is also a potential biomarker for DLBCL and
therapeutic target250. MLL2/KMT2D is another methyltransferase and potential biomarker that is
mutated in about 90% of FL cases. Deregulation of KMT2D has been reported to produce
reduced trimethylation of H3K4 and has therapeutic potential as a target. Mutations in KMT2D
along with CREBBP are suggested to be early oncogenic events251. Hypermethylation of MGMT
promoter has been associated with good prognosis252. Among tumor suppressor genes with
epigenetic modification is KLF4, which is hypermethylated in B cells in FL. Epigenetic silencing
of KLF4 may be beneficial for patients and has potential prognostic value253. P16/INK4 is a
CDK4 inhibitor, methylation in its promoter leads to inactivation of the gene, which according to
some studies may be an indication of poor prognosis in FL patients254. MEF2 encodes
transcription factors that control cell differentiation and recruit histone-modifying enzymes,
mutations in MEF2 are associated with malignant transformation of germinal center (GC) B cells
and dysregulation of BCL6 a sign of DLBCL transformation 255. Non-silent-mutations in other
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relevant epigenetic modifiers are found in ARID1A, EP300, KTM2C and BCL7, some of them
part of the m7-FLIPI256.

IL2-R

Interleukin-2 Receptor (IL-2) has been another promising potential biomarker that has
been linked to FL in multiple studies. In one study soluble IL-2 (sIL-2) was significantly
correlated with the clinical stages of FL, as well as the quantity of nodal regions257. Another
study showed that the levels of IL-2R regressed over time as patients received rituximab
treatment, and that increased levels of IL-2R was an indicator of disease progression. Among a
comparison of other cytokines, this study also reported that IL-2R levels were the only ones to
achieve statistical significance in a cohort of patients (84% elevated, P=0.04)258. An additional
study showed the usefulness of sIL-2R as a prognostic index for FL in the gastrointestinal
tract259. Together these studies showed the usefulness of IL-2R as a biomarker before treatment,
but it wasn’t until 2017 that a study demonstrated its usefulness post-treatment as well. This
study involved rituximab in combination with other drugs to provide chemotherapy (R-CHOP),
and high post-treatment sIL-2R was shown to be correlated with inferior Progression-free
survival (PFS), demonstrating IL-2R’s usefulness in post-treatment assessment as well260. In
addition, high serum sIL-2R has been shown not only to be correlated with PFS, but with Overall
Survival (OS) and Disease Specific Survival (DSS) as well261.
Other Serum cytokines

Serum cytokines levels can be useful to predict how patients may respond to certain
treatments. When compared to healthy controls, FL patients have higher levels of IL-1Ra, IL-6,
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IL-7, IL-10, IL-13, TNF-α, VEGF, and PDGF3262. Further studies at the University of Iowa and
Mayo Clinic have linked the expression of these cytokines to poor disease outcomes.
Upregulation of IL-1Ra indicated negative patient outcome in newly diagnosed patients. IL-12
and CXCL9 were also associated with decreased survival263. In addition, increased levels of
CXCL9 and CXCL10 correlated with a lower lymphocyte to monocyte ratio, another indicator of
poor prognosis5. Multivariate analysis of TGF-β and VEGF is another predictive method, with
high TGF-β and low VEGF resulting in improved outcomes258. Patients with higher
concentrations of serum IL-6 and TNF-α displayed higher tumor burden and inferior survival264.
Studies have also investigated the impact of cytokines on different treatment options. The
University of Iowa/Mayo Clinic study reported poor outcomes of alkylator and anthracyclinebased chemotherapies with high levels of IL-1Ra and IL-12265. Another article demonstrated that
increased IL-12 negatively impacted responses to rituximab antibody therapy266. In a CD19 CAR
T cell clinical trial, it was found that IL-15 was positively associated with the efficacy of the
treatment267. Overall, serum cytokines are promising biomarkers because of their potential to
represent the tumor microenvironment and predict disease outcomes.

Circulating tumor DNA

Circulating cell free DNA (cfDNA) are DNA fragments coming from cells that are
released to the blood plasma. The cfDNA coming from tumor cells is called tumor circulating
DNA (ctDNA) and can be released to the blood plasma even from deep tissues268. This ctDNA
can carry all the specific genetic aberrations characteristic of the cancer type, making it a highly
specific biomarker. Through quantitative PCR (qPCR). digital droplet PCR (ddPCR) and next
generation sequencing (NGS) specific mutations or chromosomal rearrangements unique to
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specific for FL can be detected such as the t(14;18) translocation. In a recent study conducted at
Stanford University ctDNA was used to differentiate patients with indolent FL from those
undergoing transformation to DLBCL. Using NGS the authors found ctDNA carrying FL and
DLBCL specific genetic aberrations in 100% of the patients and were able to differentiate
indolent FL cases from those transitioning to DLBCL with a 99.8% specificity269. The use of
ctDNA has demonstrated capacity to predict clinical outcomes and represents a non-invasive
method to diagnose and manage FL patients (Table 4-1).
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Table 4-1. Predictive biomarkers for follicular lymphoma and their detection methods.
Type

Biomarker

Detection method

Translocations and gene

t(14;18)(q32;q21), MYC, BCL2

PCR, FISH

CD19, CD20, CD22, CD79a,

IHC, flow cytometry

rearrangements
Histological biomarkers

CD10, BCL2, CD5, CD11c,
CD23, CD43 and CD10
Mutational status of FL related

CDNK2A, CDKN2B, TP53,

genes

BCL2, TNFRSF14, BCL6,

NGS

RHOH/TFF, PIM1, PAX5,
IRF4, ST6GAL1, BCL7A,
CIITA, LRMP, SOCS1,
MYD88, CXCR4. STAT6,
TNFAIP3, IRF8 and ETS1
Epigenetic changes

EZH2, MLL2/KMT2D,

NGS, methyl-seq

CREBBP, MGMT, KLF4,
P16/INK4, MEF2, BCL6,
ARID1A, ARID1A, KTM2C,
BCL7
Gene expression signatures

Teff 6-gene (GZMA, GZMB,

Microarray, NGS

PRF1, IFNg, EOMES, and
CD8A.
23 gene signature
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Serum cytokines

IL1R. IL2R, IL-6, IL-7, IL-10,

Immunoassay, cytokine

IL-13, TNF-α, VEGF, PDGF3,

microbeads array and flow

CXCL9, CXCL10, TGF-β, IL-

cytometry

12, IL-15
Non-malignant immune subsets

MO&MØ

Flow cytometry, histology, NGS

CD14+SIRPαhi/CD14−SIRPαlow,
MØ CD163/CD68, CD4+ and
CD8+ T cells
ctDNA

t(14;18), IGH-BCL2,

PCR, droplet PCR, NGS

MYD88 L265P, CARD11,
PIM1

MicroRNAs

44 signature

microRNA profiling (NGS,

miRNA-17-92, miR-9, miR-

microRNA microarray)

155, miR-217, miR-222, miR223. and miR-494
Exosomes

tetraspanins, CD63, CD81 and

Exosome isolation,

CD9, CD20, MHC II, AKT

immunoassay, microRNA

mRNA, BCL6 mRNA, MYC

profiling (NGS, microRNA

mRNA, PTEN mRNA, BCL-XL

microarray)

mRNA
Pyrimidine salvage pathway

TK1, HPRT

Immunoassay, IHC, Flow
cytometry
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MicroRNAs

MicroRNAs are small non-coding RNAs that regulate gene expression silencing
messenger RNA (mRNA) by binding to their 3’ untranslated region270. MicroRNAs (miRNA)
participate in tumorigenesis and have a characteristic signature in FL. Wang et al. researched the
role of miRNAs in FL and identified 44 miRNAs that were divided in three signatures that can
be used to identify patients that have an improved response to chemotherapy. The study further
identified microRNAs with tumor suppressor properties, cell cycle regulation and cytokine
signaling271. Among the most important miRNAs that can have potential as biomarkers are the
miR-17-92 cluster which includes six different miRNAs. This set of miRNAs are found to be
overexpressed in FL and promote proliferation, inhibit apoptosis, induce angiogenesis, activate
transcription signaling and cooperates with MYC, possibly targets PTEN, p21, Bim and E2F272.
Other miRNAs with diagnostic potential in FL are miR-9, miR-155, miR-217, miR-222, miR223. And miR-494273.

Exosomes

Exosomes are extracellular vesicles (40-120 nm) from endocytic origin that facilitate the
communication between cells at close and far proximity. Because they can be found in different
body fluids, there has been an increasing interest in using them as a source of biomarkers274.
Among some of the common proteins found in exosomes are endosome-associated proteins,
tetraspanins, CD63, CD81 and CD9. However, exosomes can also transport microRNAs, DNA,
and other proteins275. They also can deliver antigens to tumors and help promote anti-tumoral
responses, transport pathogenic proteins or transport molecules that help tumors to thrive.
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Quantification of lymphoma cell-derived exosomes (LCEV) and analysis of their cargo may be
used as predictive tools. Characterization of exosomes from FL B cells showed that LCEVs
expressed high levels of MHC I, low levels of MHC II and high levels of CD86276. Researchers
from the Spanish lymphoma oncology group analyzed the content of mRNA in exosomes
derived from FL cells in 166 patients and found that the presence of AKT mRNA predicted poor
response to rituximab. They also found that presence of BCL6 and C-MYC mRNA was indicative
of lower PFS and that low PTEN and BCL-XL mRNA may be related with relapse events27762.
Aung et al found that the release of exosomes carrying CD20 were used by B-Cell lymphoma
cells as a shield against anti-CD20 monoclonal antibody therapy and that blocking ABCA3
reduced the production of exosomes and increase the susceptibility of lymphoma B cells to
immunotherapy278.

Nucleotide salvage pathway enzymes

A significant amount of scientific evidence has shown that Thymidine Kinase 1 (TK1) is
a sensitive and reliable tumor biomarker for a broad range of malignancies including B cell
lymphomas279. Prochazka et al demonstrated that high TK1 serum levels in FL patients predicted
lower complete response (CR), OS and PFS. Moreover, TK1 levels were able to predict relapse
events and when combined with β2M and FLIPI help to refine risk assessment. Silencing of
TK1 has shown to decrease tumor cell proliferation, cell migration and mesenchymal
transformation of both pancreatic and lung cancer cells280. Recent findings have shown that TK1
mRNA is present in exosomes and some forms of the enzyme seem to be associated with the cell
membrane of GC B cell lymphoma cells such as Burkitt’s lymphoma81,281. Furthermore
immunotargeting of TK1 with monoclonal antibodies lead to increased killing of cancer cells by
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human MNC cells191. Another nucleotide salvage pathway enzyme with an emerging role as a
tumor biomarker is hypoxanthine phosphoribosyltransferase (HPRT). Although it was initially
considered as a housekeeping gene, recent evidence shows that HPRT is upregulated multiple
cancers and may be a suitable biomarker for B cell lymphomas99. In addition, HPRT surface
expression has also been reported in lymphoma B cells and may have a dual role as both a tumor
biomarker and a therapeutic target10070.

Conclusion

Over the last two decades the prognostic models FLIPI, FLIPI-2, tumor burden
measurements and traditional histologic analysis have been the main tools to diagnose and
manage FL patients. Although successful in some extent, these diagnostic tools have not been
sufficient to reach a consensus about therapy regimens, nor increase our ability to anticipate
relapse and refractory events, and transformation to DLBCL. With the discovery of new drugs
and development of novel immunotherapies the prognostic tools of the past may not reflect the
current course of FL disease. A more detailed genetic profiling, characterization of mutational
landscape and epigenetic modifications of FL in combination with a better understanding of the
tumor microenvironment has the potential of producing better prognostic models to diagnose,
manage and treat FL patients in the era of precision medicine.
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APPENDIX 1: Biomarker analysis and clinical relevance of TK1 on the cell membrane of
Burkitt's lymphoma and acute lymphoblastic leukemia.
Citation: Weagel EG, Meng W, Townsend MH, Velazquez E J, Brog RA, Boyer MW, Weber,
KS, Robison RA & O'Neill KL. Biomarker analysis and clinical relevance of TK1 on the cell
membrane of Burkitt's lymphoma and acute lymphoblastic leukemia. Onco Targets Ther.
2017;10:4355-4367. https://doi.org/10.2147/OTT.S141239.
I hereby confirm that the use of this article is compliant with all publishing agreements.
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APPENDIX 2: Membrane expression of thymidine kinase 1 and potential clinical relevance in
lung, breast, and colorectal malignancies.
Citation: Weagel EG, Burrup W, Kovtun R, Velazquez EJ, Felsted AM, Townsend MH, Ence
ZE, Suh E, Piccolo SR, Weber KS, Robison RA & O'Neill KL. Membrane expression of
thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies.
Cancer Cell Int. 2018;18:135. https://doi.org/10.1186/s12935-018-0633-9.
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APPENDIX 3: Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine
guanine phosphoribosyltransferase on the plasma membrane.
Citation: Townsend MH, Anderson MD, Weagel EG, Velazquez EJ, Weber KS, Robison RA, &
O'Neill KL. Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine
guanine phosphoribosyltransferase on the plasma membrane. Onco Targets Ther. 2017;10:19211932. https://doi.org/10.2147/OTT.S128416.
I hereby confirm that the use of this article is compliant with all publishing agreements.
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APPENDIX 4: Development of a TK1 specific chimeric antigen receptor T-cell for the treatment
of non-small-cell lung cancer
Citation: Edwin J. Velazquez, Kiara Vaden, Michelle H. Townsend, Evita G. Weagel, Scott
Weber, Richard A. Robison, Kim L. O'Neill. Development of a TK1 specific chimeric antigen
receptor T-cell for the treatment of non-small-cell lung cancer. Cancer Res 2017. Abstract 5619.
doi:10.1158/1538-7445.AM2017-5619
The following appendix was a published abstract in Cancer Research. This data was also
presented at the American Association for Cancer Research Annual Meeting in 2017. I hereby
confirm that the use of this abstract is compliant with all publishing agreements.
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Abstract
Our current research explores the development and tumoricidal activity of chimeric
antigen receptor T-cells targeting a new immunotherapeutic target, thymidine kinase 1 (TK1),
against non-small lung cancer (NSCLC), both in vitro and in vivo. There has been recent success
utilizing CAR T-cell therapy in clinical trials, but it has been mainly focused on the treatment of
hematological malignancies targeting CD19. Lung cancer is the most common cause of cancer
mortality globally and is responsible for more than one million of deaths every year. Moreover,
NSCLC comprises approximately 85 % of all lung cancers. Clinical trials against NSCLC using
engineered T-cells targeting NY-ESO-1, VEGFR2, MAGE-A3, and mesothelin are currently
ongoing. In spite of efforts to find new molecular targets, CAR T-cell therapy still faces several
challenges in the treatment of solid malignancies due to the lack of specific molecular targets.
We have previously reported the up-regulation of TK1 in multiple malignant tissues including
lung cancer tissues and the presence of TK1 on the cell surface of different NSCLC cell lines,
such as H460 and A549. Flow cytometry, scanning electron microscopy and confocal
microscopy showed evidence of TK1 on the surface of these cancer cells lines. We have built
third generation TK1-CARs with lentiviral and retroviral vectors. The constructions include a
single chain variable fragment for TK1, a CD28 and 4-1BB moieties connected with a CD3ζ
signaling domain. Confirmation of the CAR expression on transduced human T cells was
performed by flow cytometry and confocal microscopy, and approximately 60 % of the
transduced T-cells expressed TK1-CARs. Upon co-culturing TK1-CAR T-cells there was a
significant increase in T-cell activity and cancer cell lysis elevated as high as 48% in comparison
to negative controls. Cytokine profiles revealed a significant increase of the levels of IL-2 and
IFN-γ after 24 hr. of co-culturing, indicating T-cell activation. TK1-CAR T-cells, untransduced
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T-cells, and transduced T-cells with empty vectors were co-cultured with H460 cells and timelapse videos were recorded, every 5 minutes between 12 and 24 hr. post transduction. Clustering
of TK1-CAR T-cells around lung cancer cells and induction of cell death after T-cell synapsis
with target cells was observed. Preliminary in vitro data has shown that TK1-CAR T-cells induce
specific cell lysis in NSCLC cells. In vivo experiments using xenografts models in SNG mice
will be performed. Statistical differences between survival curves of mice treated with TK1 CAR
T-cells, untransduced T-cells and transduced T-cells with empty vectors are expected.
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APPENDIX 5: Macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a
novel adoptive cell therapy for the treatment of solid malignancies
Citation: Edwin J. Velazquez, John E. Lattin, Taylor D. Brindley, Zachary Z. Reinstein, Roger
Chu, Lu Liu, Evita G. Weagel, Michelle H. Townsend, Kiara V. Whitley, Eliza L. Lawrence,
Brandon T. Garcia, Scott Weber, Richard A. Robison, Kim L. O'Neill. Macrophage Toll-like
receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the
treatment of solid malignancies. Cancer Res 2018. Abstract 2563. DOI: 10.1158/15387445.AM2017-5619
The following appendix is a published abstract in Cancer Research. This data was also
presented at the American Association for Cancer Research Annual Meeting in 2018. I hereby
confirm that the use of this abstract is compliant with all publishing agreements.
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Abstract

Recent clinical trials using chimeric antigen receptors (CAR) T cells have demonstrated
tremendous success in eradicating hematologic malignancies. Notwithstanding the excitement
generated by CAR T cell therapy, its clinical efficacy has not been effectively translated to the
context of solid tumors; the physical barriers of solid malignancies and the immunosuppressive
conditions at the tumor site hinder the efficacy of CAR T cells. Macrophages have the ability to
infiltrate almost every tissue and frequently are recruited into tumors. Therefore, macrophages
are an attractive vehicle for CAR therapy and could help solve current challenges that CAR T
cells face in the treatment of solid tumors. MOTO-CAR cells are monocyte-derived human
macrophages that are genetically modified by a lentiviral or adenoviral approach to express a
synthetic tumor-targeting receptor and to secrete cytokines, ligands or chemokine receptors.
MOTO-CAR receptors are composed of a single-chain variable fragment (ScFv) that binds to a
specific tumor target, a hinge to link it to a transmembrane domain, and an engineered
Toll/Interleukin-1 receptor (TIR) signaling domain. When the ScFv binds to the tumor cell via its
tumor target, an activation signal is transmitted. Myd88 dependent and independent signaling
cascades are elicited, activating the macrophage and polarizing it towards a proinflammatory
phenotype to eliminate cancer cells in a selective way. We previously reported the expression of
Thymidine Kinase 1 (TK1) on the cell membrane of the non-small cell lung carcinoma NCIH460 and A549 cell lines. The in vitro function of TK1 MOTO-CAR cells was evaluated against
these cancer cell lines, using GFP-based phagocytosis and killing assays. Additionally, cell
migration and interaction was recorded using time-lapse video with a confocal microscope. Upon
co-culturing, with its target TK1 specific MOTO-CARs showed a nearly 4-fold increase in
killing activity when compared with the controls (p<0.01). MOTO-CAR cells were produced
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through a lentiviral approach with around 30% of the cells expressing MOTO-CARs and with an
adenoviral approach using the Ad5f35 vector with an efficiency of 70-80% of cells being
transduced. Furthermore, after transduction MOTO-CAR cells showed a consistent M1
phenotype expressing high levels of CD14, CD80, CD206 and low levels of CD163. Time-lapse
videos showed migration and clustering of MOTO-CAR cells around H460 GFP + cells.
Moreover, cell death was observed upon contact of MOTO-CAR cells with target cells as well as
phagocytic activity. In vivo testing using an orthotopic NOD scid gamma mice model is in
progress. Our preclinical data show evidence that human macrophages are a suitable vehicle for
CAR therapy and have the potential to successfully extrapolate the clinical efficacy of CAR
therapy to the context of solid tumors.
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APPENDIX 6: Publications generated during the PhD program
First author publications
1. Velazquez EJ, Brindley TD, Shrestha G, Bitter EE, Cress JD, Townsend MH, Berges
BK, Robison RA, Weber KS and Kim L O’Neill (2020). Novel monoclonal
antibodies against thymidine kinase 1 and their potential use for the immunotargeting
of lung, breast and colon cancer cells. Cancer Cell Int. 2020;20:127.
https://doi.org/10.1186/s12935-020-01198-8.
2. Velazquez EJ, Cress JD, Humpherys TB, Smith KR, Bellini DM, Skidmore JR,
Ewell ZD, Whitley KV, Robison RA, O’Neill KL. Selection of human single domain
antibodies against thymidine kinase through phage display and their incorporation
into sdAb-Fc antibody constructs for potential use in cancer therapy. PLOS ONE.
2022;17(3):e0264822, https://doi.org/ 10.1371/journal.pone.0264822.
3. Velazquez EJ, Bellini DM, Cress JD, O’Neill KL. Predictive biomarkers in follicular
lymphoma: current advances and future challenges. EMJ (in review).
4. Velazquez EJ, Bellini DM, Skabelund RA, Humpherys TB, Pickett BE, Piccolo SR,
O’Neill KL. Bioinformatic Analysis of The Tumor Biomarker Thymidine Kinase 1:
Elucidating its Cancer Gene Network and Membrane Expression Across All Cancers.
(Manuscript in preparation)

Publications as coauthor
1. Weagel EG, Burrup W, Kovtun R, Velazquez EJ, Felsted AM., Townsend MH,
Zachary EE., Suh E, Piccolo SR, Weber SK, Robison RA, O’Neill KL (2018)
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Membrane expression of thymidine kinase 1 and potential clinical relevance in lung,
breast, and colorectal malignancies. Cancer Cell Int. 2018;18:135.
doi:0.1186/s12935-018-0633-9
2. Weagel EG, Meng W, Townsend MH, Velazquez EJ, Brog RA, Boyer MW, Weber
SK, Robison RA, O’Neill KL (2017). Biomarker analysis and clinical relevance of
TK1 on the cell membrane of Burkitt’s lymphoma and acute lymphoblastic leukemia.
OncoTargets and Therapy. 2017;10:4355–4367.doi:10.2147/OTT.S141239.
3. Townsend MH, Anderson MD, Weagel EG, Velazquez EJ, Weber KS, Robison RA,
and O’Neill KL (2017). Non-Small Cell Lung Cancer Cell Lines A549 and NCIH460 Express HPRT on the Plasma Membrane. Oncotargets & Therapy. 2017:10
1921-1932. Doi.org/10.2147/OTT.S128416.
Book chapters

1. Edwin J. Velazquez, Taylor D Brindley, Gajendra Shrestha, Eliza E Bitter, Jordan D
Cress, Michelle H Townsend, Bradford K Berges, Richard A Robison, K Scott Weber
and Kim L O’Neill (2021). Novel monoclonal antibodies against thymidine kinase 1 and
their potential use for the immunotargeting of lung, breast and colon cancer cells. Prime
Archives in Cancer Research, Vide Leaf.
PRESENTATIONS
Oral presentations
Oral talk given at the Biomedical West Regional Conference on January 19, 2017
entitled, “Chimeric Antigen Receptor (CARs) for Thymidine Kinase 1 (TK1): A novel
immunotherapy approach to fight cancer.”
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Poster presentations
1. Edwin J Velazquez, Tyler B Humpherys, Toni O Mortimer, David M Bellini,
Kathryn R Smith, Rachel M Morris, Abigail Goodman, Kim L O’Neill. Isolation and
Evaluation of Human Nanobodies Against Hypoxanthine Guanine
Phosphoribosyltransferase (HPRT) and Their Potential Use for The Detection and
Targeting of Lung, Breast and Colon Cancer Cells. American Association for Cancer
Research annual meeting 2021. Virtual meeting.
2. Edwin J Velazquez, David M Bellini, Rachel A. Skabelund, Tyler B Humpherys,
Jonathan R Skidmore, Brett E Pickett, Stephen R Piccolo, Kim L O’Neill.
Bioinformatic analysis of the tumor biomarker thymidine kinase 1: elucidating its
cancer gene network and membrane expression across all cancers. American
Association for Cancer Research annual meeting 2021. Virtual meeting.

3. Edwin J. Velazquez, John E. Lattin, Taylor D. Brindley, Zachary Z. Reinstein,
Roger Chu, Lu Liu, Evita G. Weagel, Michelle H. Townsend, Kiara V. Whitley, Eliza
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Hypoxanthine Guanine Phosphoribosyltransferase expression in prostate cancer and
its implication on therapy. American Society of Microbiologists Intermountain
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180
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20. Michelle H. Townsend, Abi M. Felsted, Edwin J. Velazquez, Evita G. Weagel,
Richar A. Robison, and Kim L. O’Neill (2017). Is Interleukin-10 a key factor in colon
cancer metastasis? 56th Midwinter conference of immunologists, Monterrey,
California, USA.
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Velazquez, Toshiko A. L. Becker, C. A. Mekia, Michael R. Downey, Juan A.
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thymidine kinase 1 as a new immunotherapy target. American Association for Cancer
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22. R.A. Brog, E.G. Weagel, W. Meng, M.H. Townsend, E.J. Velazquez, R.A. Robison,
K.L O’Neill (2016). Breast cancer cells suppress macrophage aggressiveness. 55th
Midwinter Conference of Immunologist, 2016. Monterrey, CA, USA.
23. Michelle Townsend, E.G. Weagel, W. Meng, R.A. Brog, E.J. Velazquez, R.A.
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AWARDS AND SCHOLARSHIPS
•

2021 Distinguished Graduate Student Award

Department of Microbiology and Molecular Biology. April 2021

•

Summer fellowship

Simmons Center for Cancer Research. Apr 2020-Aug 2020

Winner of the poster presentation session
Intermountain Biological Engineering Conference 2019. March 2019

Award for outstanding student presentation
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Microbiology and molecular biology graduate retreat. Aug 2020

Winner of the poster presentation session
ACEA Biosciences, a part of Agilent’s, 7th Annual Cancer and Immunotherapy symposium. Apr
2019

Jau-Fei Chen scholarship for immunology related research
Microbiology and Molecular Biology Department. Sep 2018-Apr 2019

Year-round fellowship
Simmons Center for Cancer Research. Sep 2017-Aug 2018

Summer fellowship
Simmons Center for Cancer Research. Apr 2017-Aug 2017

Winner of the poster presentation session
American Society of Microbiologists (ASM). March 2017

Scholarship for the support of doctoral degree studies abroad
National Council of Science and Technology of Mexico. Sep 2015-Aug 2020

TOTAL FUNDING ATTRACTED
~ $82,500.00
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MEMBERSHIPS
American Association for Cancer Research (AACR)

Dec 2016-Present

Associate member
CONFERENCES assisted
•

American Association for Cancer Research Annual Meeting, Virtual meeting,
2021

•

American Association for Cancer Research Annual Meeting, Virtual meeting,
2020

•

American Association for Cancer Research Annual Meeting, Atlanta, Georgia,
2019

•

ACEA Biosciences, 7th Annual Cancer and Immunotherapy symposium, Atlanta,
Georgia, 2019

•

Intermountain Biological Engineering Conference Salt Lake City, 2019

•

American Association for Cancer Research Annual Meeting Chicago, Illinois,
2018

•

American Society of Microbiology intermountain branch regional meeting, Provo,
Utah 2018

•

American Association for Cancer Research Annual Meeting, Washington D.C.,
2017

•

American Society of Microbiology intermountain branch regional meeting 2017

•

56th Midwinter Conference of Immunologist, Monterrey, California, 2017

•

American Association for Cancer Research Annual Meeting 2016

•

55th Midwinter Conference of Immunologist, Monterrey, California, 2016
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